Raras
Buscar doenças, sintomas, genes...
Alteração do metabolismo lipídico
ORPHA:309005CID-10 · E78.9DOENÇA RARA
neuro
Também conhecida comoDislipidémiaHiperlipoproteinemiaHiperlipidemiaDislipidemias

É uma doença genética que afeta o metabolismo, causada pela falta de uma enzima. Por causa disso, o corpo não consegue queimar as gorduras para produzir energia.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋
Informacoes curadas por IA — podem conter imprecisoes

É uma doença genética que afeta o metabolismo, causada pela falta de uma enzima. Por causa disso, o corpo não consegue queimar as gorduras para produzir energia.

Pesquisas ativas
1 ensaio
4261 total registrados no ClinicalTrials.gov
Publicações científicas
332 artigos
Último publicado: 2026
Medicamentos
18 registrados
SIMVASTATIN, EZETIMIBE, AMLODIPINE BESYLATE

Tem tratamento?

18 medicamentos registrados
Ver detalhes, fases e interações →
SIMVASTATINEZETIMIBEAMLODIPINE BESYLATEPITAVASTATIN CALCIUMALIROCUMABEVOLOCUMABEVINACUMABBEMPEDOIC ACIDATORVASTATIN CALCIUMMIPOMERSEN SODIUM
🏥
SUS: Sem cobertura SUSScore: 20%
CID-10: E78.9
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
224 sintomas
🧠
Neurológico
203 sintomas
👁️
Olhos
112 sintomas
😀
Face
102 sintomas
🫃
Digestivo
88 sintomas
💪
Músculos
87 sintomas

+ 1050 sintomas em outras categorias

Características mais comuns

Costelas curtas
Hemorragia nasal
Telangiectasias mucosas
Atividade diminuída da esfingomielinase ácida
Adelgaçamento retiniano
Acúmulo de gotículas lipídicas em enterócitos do intestino delgado
2299sintomas
Sem dados (2299)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 2299 características clínicas mais associadas, ordenadas por frequência.

Costelas curtasShort ribs
Hemorragia nasalHP:6001353
Telangiectasias mucosasMucosal telangiectasiae
Atividade diminuída da esfingomielinase ácidaDecreased acid sphingomyelinase activity
Adelgaçamento retinianoRetinal thinning

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico332PubMed
Últimos 10 anos178publicações
Pico202422 papers
Linha do tempo
2026Hoje · 2026🧪 1971Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

75 genes identificados com associação a esta condição.

APOEApolipoprotein EDisease-causing germline mutation(s) inTolerante
FUNÇÃO

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:14754908, PubMed:1911868, PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692, PubMed:9395455). Apolipoproteins are amphipathic mole

LOCALIZAÇÃO

SecretedSecreted, extracellular spaceSecreted, extracellular space, extracellular matrixExtracellular vesicleEndosome, multivesicular body

VIAS BIOLÓGICAS (9)
Nuclear signaling by ERBB4Scavenging by Class A ReceptorsTranscriptional regulation by the AP-2 (TFAP2) family of transcription factorsChylomicron assemblyHDL remodeling
MECANISMO DE DOENÇA

Hyperlipoproteinemia 3

A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause.

OUTRAS DOENÇAS (6)
lipoprotein glomerulopathyhyperlipoproteinemia type 3sea-blue histiocyte syndromeAlzheimer disease 2
HGNC:613UniProt:P02649
IBA57Iron-sulfur cluster assembly factor IBA57, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial protein involved in the maturation of mitochondrial [4Fe-4S]-proteins in the late stage of the iron-sulfur cluster assembly pathway (PubMed:22323289, PubMed:23462291). Operates in cooperation with ISCA2 in the maturation of [4Fe-4S] proteins (PubMed:30269484) Involved in the maturation of mitochondrial 2Fe-2S proteins in the late stage of the iron-sulfur cluster assembly pathway

LOCALIZAÇÃO

Mitochondrion

MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 3

A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. Some patients show failure to thrive, pulmonary hypertension, hypotonia and irritability. Biochemical features include severe combined deficiency of the 2-oxoacid dehydrogenases, defective lipoic acid synthesis and reduction in activity of mitochondrial respiratory chain complexes.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
9.4 TPM
Cérebro - Hemisfério cerebelar
4.7 TPM
Cerebelo
4.4 TPM
Útero
4.3 TPM
Ovário
4.1 TPM
OUTRAS DOENÇAS (2)
multiple mitochondrial dysfunctions syndrome 3hereditary spastic paraplegia 74
HGNC:27302UniProt:Q5T440
GALCGalactocerebrosidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the galactose ester bonds of glycolipids such as galactosylceramide and galactosylsphingosine (PubMed:8281145, PubMed:8399327). Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon (PubMed:8281145, PubMed:8399327)

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Krabbe disease

An autosomal recessive disorder characterized by insufficient catabolism of several galactolipids that are important for normal myelin production. Four clinical forms are recognized. The infantile form accounts for 90% of cases. It manifests before six months of age with irritability, spasticity, arrest of motor and mental development, and bouts of temperature elevation without infection. This is followed by myoclonic jerks of arms and legs, oposthotonus, hypertonic fits, and mental regression, which progresses to a severe decerebrate condition with no voluntary movements and death from respiratory infections or cerebral hyperpyrexia before 2 years of age. Cases with later onset present with unexplained blindness, weakness and sensorimotor peripheral neuropathy, mental deterioration and death.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
31.7 TPM
Testículo
28.0 TPM
Brain Spinal cord cervical c-1
26.5 TPM
Pulmão
25.7 TPM
Ovário
22.2 TPM
OUTRAS DOENÇAS (4)
Krabbe diseaseinfantile Krabbe diseaseadult Krabbe diseaselate-infantile/juvenile Krabbe disease
HGNC:4115UniProt:P54803
ECM1Extracellular matrix protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in endochondral bone formation as negative regulator of bone mineralization. Stimulates the proliferation of endothelial cells and promotes angiogenesis. Inhibits MMP9 proteolytic activity

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (1)
Platelet degranulation
MECANISMO DE DOENÇA

Lipoid proteinosis

Rare autosomal recessive disorder characterized by generalized thickening of skin, mucosae and certain viscera. Classical features include beaded eyelid papules and laryngeal infiltration leading to hoarseness. Histologically, there is widespread deposition of hyaline material and disruption/reduplication of basement membrane.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
987.1 TPM
Vagina
235.0 TPM
Fibroblastos
71.1 TPM
Skin Sun Exposed Lower leg
63.2 TPM
Cervix Ectocervix
60.3 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
lipoid proteinosis
HGNC:3153UniProt:Q16610
NPC2NPC intracellular cholesterol transporter 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Intracellular cholesterol transporter which acts in concert with NPC1 and plays an important role in the egress of cholesterol from the lysosomal compartment (PubMed:11125141, PubMed:15937921, PubMed:17018531, PubMed:18772377, PubMed:29580834). Unesterified cholesterol that has been released from LDLs in the lumen of the late endosomes/lysosomes is transferred by NPC2 to the cholesterol-binding pocket in the N-terminal domain of NPC1 (PubMed:17018531, PubMed:18772377, PubMed:27238017). May bind

LOCALIZAÇÃO

SecretedEndoplasmic reticulumLysosome

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Niemann-Pick disease C2

A lysosomal storage disorder that affects the viscera and the central nervous system. It is due to defective intracellular processing and transport of low-density lipoprotein derived cholesterol. It causes accumulation of cholesterol in lysosomes, with delayed induction of cholesterol homeostatic reactions. Niemann-Pick disease type C2 has a highly variable clinical phenotype. Clinical features include variable hepatosplenomegaly and severe progressive neurological dysfunction such as ataxia, dystonia and dementia. The age of onset can vary from infancy to late adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
220.1 TPM
Pulmão
217.6 TPM
Cervix Endocervix
153.6 TPM
Ovário
144.8 TPM
Aorta
132.6 TPM
OUTRAS DOENÇAS (6)
Niemann-Pick disease, type C2Niemann-Pick disease type C, severe perinatal formNiemann-Pick disease type C, severe early infantile neurologic onsetNiemann-Pick disease type C, juvenile neurologic onset
HGNC:14537UniProt:P61916
GLB1Beta-galactosidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans Has no beta-galactosidase catalytic activity, but plays functional roles in the formation of extracellular elastic fibers (elastogenesis) and in the development of connective tissue. Seems to be identical to the elastin-binding protein (EBP), a major component of the non-integrin cell surface receptor expressed on fibroblasts, smooth muscle cells, chondroblasts, leukocytes, and certain cance

LOCALIZAÇÃO

LysosomeCytoplasm, perinuclear region

VIAS BIOLÓGICAS (5)
Sialic acid metabolismGlycosphingolipid catabolismCS/DS degradationKeratan sulfate degradationDefective NEU1 causes sialidosis
MECANISMO DE DOENÇA

GM1-gangliosidosis 1

An autosomal recessive lysosomal storage disease marked by the accumulation of GM1 gangliosides, glycoproteins and keratan sulfate primarily in neurons of the central nervous system. GM1-gangliosidosis type 1 is characterized by onset within the first three months of life, central nervous system degeneration, coarse facial features, hepatosplenomegaly, skeletal dysmorphology reminiscent of Hurler syndrome, and rapidly progressive psychomotor deterioration. Urinary oligosaccharide levels are high. It leads to death usually between the first and second year of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
68.5 TPM
Tireoide
44.2 TPM
Glândula adrenal
40.6 TPM
Cervix Endocervix
35.2 TPM
Pulmão
35.1 TPM
OUTRAS DOENÇAS (4)
mucopolysaccharidosis type 4BGM1 gangliosidosis type 2GM1 gangliosidosis type 3GM1 gangliosidosis type 1
HGNC:4298UniProt:P16278
MVKMevalonate kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the phosphorylation of mevalonate to mevalonate 5-phosphate, a key step in isoprenoid and cholesterol biosynthesis (PubMed:11278915, PubMed:18302342, PubMed:9325256, PubMed:9392419)

LOCALIZAÇÃO

CytoplasmPeroxisome

VIAS BIOLÓGICAS (2)
Lanosterol biosynthesisActivation of gene expression by SREBF (SREBP)
MECANISMO DE DOENÇA

Mevalonic aciduria

Accumulation of mevalonic acid which causes a variety of symptoms such as psychomotor retardation, dysmorphic features, cataracts, hepatosplenomegaly, lymphadenopathy, anemia, hypotonia, myopathy, and ataxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
41.6 TPM
Esôfago - Mucosa
40.7 TPM
Skin Sun Exposed Lower leg
34.1 TPM
Rim - Medula
33.4 TPM
Skin Not Sun Exposed Suprapubic
32.7 TPM
OUTRAS DOENÇAS (5)
mevalonic aciduriaporokeratosis 3, disseminated superficial actinic typehyperimmunoglobulinemia D with periodic feverporokeratosis of Mibelli
HGNC:7530UniProt:Q03426
ETFDHElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Accepts electrons from ETF and reduces ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Respiratory electron transport
MECANISMO DE DOENÇA

Glutaric aciduria 2C

An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
51.2 TPM
Fígado
43.3 TPM
Glândula adrenal
41.9 TPM
Músculo esquelético
41.7 TPM
Coração - Átrio
38.5 TPM
OUTRAS DOENÇAS (3)
multiple acyl-CoA dehydrogenase deficiencymultiple acyl-CoA dehydrogenase deficiency, severe neonatal typemultiple acyl-CoA dehydrogenase deficiency, mild type
HGNC:3483UniProt:Q16134
FDXRNADPH:adrenodoxin oxidoreductase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver (By similarity). Also acts as a ferredoxin--NADP(+) reductase essential for coenzyme Q biosynthesis: together with FDX2, transfers the electrons required for the hydroxylation reaction performed by C

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Electron transport from NADPH to FerredoxinEndogenous sterolsPregnenolone biosynthesisDefective CYP11A1 causes AICSR
MECANISMO DE DOENÇA

Auditory neuropathy and optic atrophy

An autosomal recessive disease characterized by hearing loss, visual impairment and optic atrophy, with onset in the first or second decades of life. Optic atrophy is caused by degeneration of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
302.8 TPM
Testículo
77.8 TPM
Baço
43.0 TPM
Linfócitos
37.8 TPM
Ovário
37.6 TPM
OUTRAS DOENÇAS (3)
multiple mitochondrial dysfunctions syndrome 9bauditory neuropathy-optic atrophy syndromeoptic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome
HGNC:3642UniProt:P22570
LBRDelta(14)-sterol reductase LBRDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Catalyzes the reduction of the C14-unsaturated bond of lanosterol, as part of the metabolic pathway leading to cholesterol biosynthesis (PubMed:12618959, PubMed:16784888, PubMed:21327084, PubMed:27336722, PubMed:9630650). Plays a critical role in myeloid cell cholesterol biosynthesis which is essential to both myeloid cell growth and functional maturation (By similarity). Mediates the activation of NADPH oxidases, perhaps by maintaining critical levels of cholesterol required for membrane lipid

LOCALIZAÇÃO

Nucleus inner membraneEndoplasmic reticulum membraneCytoplasmNucleus

VIAS BIOLÓGICAS (3)
Initiation of Nuclear Envelope (NE) ReformationCholesterol biosynthesis via desmosterol (Bloch pathway)Regulation of MECP2 expression and activity
MECANISMO DE DOENÇA

Pelger-Huet anomaly

An autosomal dominant inherited abnormality of granulocytes, characterized by abnormal ovoid shape, reduced nuclear segmentation and an apparently looser chromatin structure.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon sigmoide
89.3 TPM
Linfócitos
88.9 TPM
Útero
68.5 TPM
Esôfago - Muscular
63.1 TPM
Cervix Ectocervix
54.0 TPM
OUTRAS DOENÇAS (4)
Greenberg dysplasiaregressive spondylometaphyseal dysplasiaPelger-Huet anomalyReynolds syndrome
HGNC:6518UniProt:Q14739
GLAN-acetyltransferase 8Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Endoplasmic reticulum (ER)-membrane-bound lysine N-acetyltransferase catalyzing the N6-acetylation of lysine residues in the lumen of the ER in various proteins, including PROM1 and BACE1, using acetyl-CoA as acetyl donor (PubMed:19011241, PubMed:22267734, PubMed:24556617, PubMed:31945187). Thereby, may regulate apoptosis through the acetylation and the regulation of the expression of PROM1 (PubMed:24556617). May also regulate amyloid beta-peptide secretion through acetylation of BACE1 and the r

LOCALIZAÇÃO

Endoplasmic reticulum-Golgi intermediate compartment membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
34.6 TPM
Linfócitos
33.0 TPM
Sangue
31.3 TPM
Glândula adrenal
24.7 TPM
Baço
24.7 TPM
OUTRAS DOENÇAS (1)
Fabry disease
HGNC:4296UniProt:Q9UHE5
PSAPMitochondrial carrier homolog 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Protein insertase that mediates insertion of transmembrane proteins into the mitochondrial outer membrane (PubMed:36264797). Catalyzes insertion of proteins with alpha-helical transmembrane regions, such as signal-anchored, tail-anchored and multi-pass membrane proteins (By similarity). Does not mediate insertion of beta-barrel transmembrane proteins (By similarity). May play a role in apoptosis (PubMed:12377771)

LOCALIZAÇÃO

Mitochondrion outer membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
1575.5 TPM
Baço
1390.0 TPM
Glândula adrenal
1384.0 TPM
Sangue
1315.6 TPM
Cervix Endocervix
1314.5 TPM
OUTRAS DOENÇAS (9)
Gaucher disease due to saposin C deficiencyKrabbe disease due to saposin A deficiencycombined PSAP deficiencymetachromatic leukodystrophy due to saposin B deficiency
HGNC:9498UniProt:Q9NZJ7
TJP2Tight junction protein 2Candidate gene tested inTolerante
FUNÇÃO

Plays a role in tight junctions and adherens junctions (By similarity). Acts as a positive regulator of RANKL-induced osteoclast differentiation, potentially via mediating downstream transcriptional activity (By similarity)

LOCALIZAÇÃO

Cell junction, adherens junctionCell membraneCell junction, tight junctionNucleus

VIAS BIOLÓGICAS (1)
Signaling by Hippo
MECANISMO DE DOENÇA

Hypercholanemia, familial, 1

A disorder characterized by elevated serum bile acid concentrations, itching, and fat malabsorption.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
103.6 TPM
Nervo tibial
85.5 TPM
Pulmão
84.2 TPM
Tecido adiposo
81.3 TPM
Tireoide
80.0 TPM
OUTRAS DOENÇAS (3)
cholestasis, progressive familial intrahepatic, 4hypercholanemia, familial 1autosomal dominant nonsyndromic hearing loss
HGNC:11828UniProt:Q9UDY2
PGAP3GPI-specific phospholipase A2-like PGAP3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the fatty acid remodeling steps of GPI-anchor maturation where the unsaturated acyl chain at sn-2 of inositol phosphate is replaced by a saturated stearoyl chain (PubMed:17021251, PubMed:24439110). May catalyze the first step of the fatty acid remodeling, by removing the unsaturated acyl chain at sn-2 of inositol phosphate, generating a lyso-GPI intermediate (Probable). The fatty acid remodeling steps is critical for the integration of GPI-APs into lipid rafts (By similarity)

LOCALIZAÇÃO

Golgi apparatus membrane

MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 4

An autosomal recessive neurologic disorder characterized by profound developmental delay, severe intellectual disability, no speech, psychomotor delay, postnatal microcephaly, and elevated serum alkaline phosphatase.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
66.6 TPM
Skin Sun Exposed Lower leg
41.0 TPM
Glândula salivar
38.3 TPM
Skin Not Sun Exposed Suprapubic
37.4 TPM
Cervix Endocervix
36.0 TPM
OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 4hyperphosphatasia-intellectual disability syndrome
HGNC:23719UniProt:Q96FM1
LPLLipoprotein lipaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage (PubMed:11342582, PubMed:27578112, PubMed:8675619). Although it has both phospholipase and triglyceride lipase activities it is primarily a triglyceride lipase with low but detectable phospholipase activity (PubMed:12032167, PubMed:7592706

LOCALIZAÇÃO

Cell membraneSecretedSecreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (5)
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosisTranscriptional regulation of white adipocyte differentiationAssembly of active LPL and LIPC lipase complexesChylomicron remodelingRetinoid metabolism and transport
MECANISMO DE DOENÇA

Hyperlipoproteinemia 1

An autosomal recessive metabolic disorder characterized by defective breakdown of dietary fats, impaired clearance of chylomicrons from plasma causing the plasma to have a milky appearance, and severe hypertriglyceridemia. On a normal diet, patients often present with abdominal pain, hepatosplenomegaly, lipemia retinalis, eruptive xanthomata, and massive hypertriglyceridemia, sometimes complicated with acute pancreatitis.

EXPRESSÃO TECIDUAL(Ubíquo)
Adipose Visceral Omentum
473.1 TPM
Tecido adiposo
440.4 TPM
Nervo tibial
314.1 TPM
Mama
252.6 TPM
Coração - Ventrículo esquerdo
216.0 TPM
OUTRAS DOENÇAS (2)
familial lipoprotein lipase deficiencyhyperlipidemia, familial combined, LPL related
HGNC:6677UniProt:P06858
MTTPMicrosomal triglyceride transfer protein large subunitCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces (PubMed:15897609, PubMed:16478722, PubMed:22236406, PubMed:23475612, PubMed:25108285, PubMed:26224785, PubMed:8876250, PubMed:8939939). Required for the assembly and secretion of plasma lipoproteins that contain apolipoprotein B (PubMed:16478722, PubMed:23475612, PubMed:26224785, PubMed:8876250, PubMed:8939939). May be involved in regulating cholesteryl ester biosynthesis in cells that prod

LOCALIZAÇÃO

Endoplasmic reticulumGolgi apparatus

VIAS BIOLÓGICAS (3)
VLDL assemblyChylomicron assemblyLDL remodeling
MECANISMO DE DOENÇA

Abetalipoproteinemia

An autosomal recessive disorder of lipoprotein metabolism. Affected individuals produce virtually no circulating apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, LDL, lipoprotein(A)). Malabsorption of the antioxidant vitamin E occurs, leading to spinocerebellar and retinal degeneration.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
31.1 TPM
Intestino delgado
24.7 TPM
Testículo
7.1 TPM
Ovário
1.8 TPM
Linfócitos
1.2 TPM
OUTRAS DOENÇAS (1)
abetalipoproteinemia
HGNC:7467UniProt:P55157
PEX5Peroxisomal targeting signal 1 receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor that mediates peroxisomal import of proteins containing a C-terminal PTS1-type tripeptide peroxisomal targeting signal (SKL-type) (PubMed:11101887, PubMed:11336669, PubMed:12456682, PubMed:16314507, PubMed:17157249, PubMed:17428317, PubMed:21976670, PubMed:26344566, PubMed:7706321, PubMed:7719337, PubMed:7790377). Binds to cargo proteins containing a PTS1 peroxisomal targeting signal in the cytosol, and translocates them into the peroxisome matrix by passing through the PEX13-PEX14 dock

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome matrix

VIAS BIOLÓGICAS (1)
Pexophagy
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder 2A

A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and characterized clinically by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
77.7 TPM
Cerebelo
49.0 TPM
Cérebro - Hemisfério cerebelar
48.3 TPM
Pituitária
46.8 TPM
Nervo tibial
44.2 TPM
OUTRAS DOENÇAS (5)
peroxisome biogenesis disorder 2Brhizomelic chondrodysplasia punctata type 5peroxisome biogenesis disorder 2A (Zellweger)Zellweger spectrum disorders
HGNC:9719UniProt:P50542
LDLRAP1Low density lipoprotein receptor adapter protein 1Candidate gene tested inTolerante
FUNÇÃO

Adapter protein (clathrin-associated sorting protein (CLASP)) required for efficient endocytosis of the LDL receptor (LDLR) in polarized cells such as hepatocytes and lymphocytes, but not in non-polarized cells (fibroblasts). May be required for LDL binding and internalization but not for receptor clustering in coated pits. May facilitate the endocytosis of LDLR and LDLR-LDL complexes from coated pits by stabilizing the interaction between the receptor and the structural components of the pits.

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (6)
Transport of RCbl within the bodyVitamin D (calciferol) metabolismChylomicron clearanceLDL clearanceClathrin-mediated endocytosis
MECANISMO DE DOENÇA

Hypercholesterolemia, familial, 4

A form of hypercholesterolemia, a disorder of lipoprotein metabolism characterized by elevated serum low-density lipoprotein (LDL) cholesterol levels, which result in excess deposition of cholesterol in tissues and leads to xanthelasma, xanthomas, accelerated atherosclerosis and increased risk of premature coronary heart disease. FHCL4 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
129.4 TPM
Cérebro - Hemisfério cerebelar
115.4 TPM
Baço
69.7 TPM
Brain Spinal cord cervical c-1
49.2 TPM
Aorta
34.6 TPM
OUTRAS DOENÇAS (2)
hypercholesterolemia, familial, 4homozygous familial hypercholesterolemia
HGNC:18640UniProt:Q5SW96
SRD5A23-oxo-5-alpha-steroid 4-dehydrogenase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology

LOCALIZAÇÃO

Microsome membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Androgen biosynthesis
MECANISMO DE DOENÇA

Pseudovaginal perineoscrotal hypospadias

A form of male pseudohermaphroditism in which 46,XY males show ambiguous genitalia at birth, including perineal hypospadias and a blind perineal pouch, and develop masculinization at puberty. The name of the disorder stems from the finding of a blind-ending perineal opening resembling a vagina and a severely hypospadiac penis with the urethra opening onto the perineum.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Próstata
25.8 TPM
Fígado
11.2 TPM
Testículo
3.7 TPM
Vagina
2.3 TPM
Cervix Endocervix
0.7 TPM
OUTRAS DOENÇAS (2)
46,XY disorder of sex development due to 5-alpha-reductase 2 deficiencyprostate cancer, hereditary
HGNC:11285UniProt:P31213
CYP7B1Cytochrome P450 7B1Candidate gene tested inTolerante
FUNÇÃO

A cytochrome P450 monooxygenase involved in the metabolism of endogenous oxysterols and steroid hormones, including neurosteroids (PubMed:10588945, PubMed:24491228). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:10588945, PubMed:24491228). Catalyzes the hydroxylation of carbon hydrogen bonds of stero

LOCALIZAÇÃO

Endoplasmic reticulum membraneMicrosome membrane

VIAS BIOLÓGICAS (4)
Synthesis of bile acids and bile saltsEndogenous sterolsSynthesis of bile acids and bile salts via 27-hydroxycholesterolSynthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
MECANISMO DE DOENÇA

Spastic paraplegia 5A, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
12.4 TPM
Linfócitos
9.7 TPM
Nervo tibial
8.5 TPM
Cervix Ectocervix
6.8 TPM
Pulmão
6.8 TPM
OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 5Acongenital bile acid synthesis defect 3
HGNC:2652UniProt:O75881
HEXABeta-hexosaminidase subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:8123671, PubMed:8672428, PubMed:9694901). The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated glycosphingolipid SM

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Defective HEXA causes GM2G1 (Hyaluronan metabolism)
MECANISMO DE DOENÇA

GM2-gangliosidosis 1

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the absence of HEXA activity, leading to neurodegeneration and, in the infantile form, death in early childhood. It exists in several forms: infantile (most common and most severe), juvenile and adult (late-onset).

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
43.9 TPM
Fibroblastos
39.7 TPM
Cervix Endocervix
36.7 TPM
Aorta
36.0 TPM
Pulmão
34.0 TPM
OUTRAS DOENÇAS (4)
Tay-Sachs diseaseTay-Sachs disease, b variant, infantile formTay-Sachs disease, B variant, adult formTay-Sachs disease, b variant, juvenile form
HGNC:4878UniProt:P06865
ETFBElectron transfer flavoprotein subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Heterodimeric electron transfer flavoprotein that accepts electrons from several mitochondrial dehydrogenases, including acyl-CoA dehydrogenases, glutaryl-CoA and sarcosine dehydrogenase (PubMed:15159392, PubMed:15975918, PubMed:25416781). It transfers the electrons to the main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (Probable). Required for normal mitochondrial fatty acid oxidation and normal amino acid metabolism (PubMed:12815589, PubMed:7912128). ETFB binds an AMP mo

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Respiratory electron transportProtein methylation
MECANISMO DE DOENÇA

Glutaric aciduria 2B

An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
61.0 TPM
Coração - Ventrículo esquerdo
46.4 TPM
Glândula adrenal
45.8 TPM
Fibroblastos
41.3 TPM
Coração - Átrio
39.7 TPM
OUTRAS DOENÇAS (3)
multiple acyl-CoA dehydrogenase deficiencymultiple acyl-CoA dehydrogenase deficiency, mild typemultiple acyl-CoA dehydrogenase deficiency, severe neonatal type
HGNC:3482UniProt:P38117
LIPCHepatic triacylglycerol lipaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the hydrolysis of triglycerides and phospholipids present in circulating plasma lipoproteins, including chylomicrons, intermediate density lipoproteins (IDL), low density lipoproteins (LDL) of large size and high density lipoproteins (HDL), releasing free fatty acids (FFA) and smaller lipoprotein particles (PubMed:12032167, PubMed:26193433, PubMed:7592706, PubMed:8798474). Also exhibits lysophospholipase activity (By similarity). Can hydrolyze both neutral lipid and phospholipid substr

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Assembly of active LPL and LIPC lipase complexes
MECANISMO DE DOENÇA

Hepatic lipase deficiency

A disorder characterized by elevated levels of beta-migrating very low density lipoproteins, and abnormally triglyceride-rich low and high density lipoproteins.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
26.8 TPM
Nervo tibial
5.5 TPM
Rim - Medula
3.2 TPM
Rim - Córtex
2.2 TPM
Pituitária
1.3 TPM
OUTRAS DOENÇAS (2)
hyperlipidemia due to hepatic triglyceride lipase deficiencytype 2 diabetes mellitus
HGNC:6619UniProt:P11150
LIPT1Lipoyl amidotransferase LIPT1, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Lipoyl amidotransferase that catalyzes the transfer of lipoyl moieties from lipoyl-protein H of the glycine cleavage system (lipoyl-GCSH) to E2 subunits of the pyruvate dehydrogenase complex (PDCE2) (PubMed:29987032). Unable to catalyze the transfer of octanoyl from octanoyl-GCSH to PDCE2 (PubMed:29987032). In vitro, it is also able to catalyze the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of lipoyl domains of lipoate-dependent enzymes but this reaction may not

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Protein lipoylation
MECANISMO DE DOENÇA

Lipoyltransferase 1 deficiency

An autosomal recessive disorder due to a defect in lipoic acid metabolism, resulting in severe lactic acidosis and metabolic decompensation. Variable clinical manifestations include delayed psychomotor development, severe hypotonia, dystonia, loss of head control, coma, bradycardia, and pulmonary hypertension.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
14.5 TPM
Tireoide
11.8 TPM
Baço
11.8 TPM
Ovário
11.5 TPM
Próstata
10.8 TPM
OUTRAS DOENÇAS (1)
lipoyl transferase 1 deficiency
HGNC:29569UniProt:Q9Y234
LDLRLow-density lipoprotein receptorCandidate gene tested inTolerante
FUNÇÃO

Binds low density lipoprotein /LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Forms a ternary complex with PGRMC1 and TMEM97 receptors which increases LDLR-mediated LDL internalization (PubMed:30443021) (Microbial infection) Acts as a receptor for hepatitis C virus in hepatocytes, but not through a direct interaction with viral proteins

LOCALIZAÇÃO

Cell membraneMembrane, clathrin-coated pitGolgi apparatusEarly endosomeLate endosomeLysosome

VIAS BIOLÓGICAS (5)
Chylomicron clearanceLDL clearanceClathrin-mediated endocytosisCargo recognition for clathrin-mediated endocytosisRetinoid metabolism and transport
MECANISMO DE DOENÇA

Hypercholesterolemia, familial, 1

A form of hypercholesterolemia, a disorder of lipoprotein metabolism characterized by elevated serum low-density lipoprotein (LDL) cholesterol levels, which result in excess deposition of cholesterol in tissues and leads to xanthelasma, xanthomas, accelerated atherosclerosis and increased risk of premature coronary heart disease. FHCL1 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
91.8 TPM
Pulmão
78.6 TPM
Ovário
61.5 TPM
Fibroblastos
59.4 TPM
Esôfago - Mucosa
58.4 TPM
OUTRAS DOENÇAS (2)
hypercholesterolemia, familial, 1homozygous familial hypercholesterolemia
HGNC:6547UniProt:P01130
SC5DLathosterol oxidaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the penultimate step of the biosynthesis of cholesterol, the dehydrogenation of lathosterol into 7-dehydrocholesterol (7-DHC). Cholesterol is the major sterol component in mammalian membranes and a precursor for bile acid and steroid hormone synthesis (PubMed:10786622, PubMed:38297129). In addition to its essential role in cholesterol biosynthesis, it also indirectly regulates ferroptosis through the production of 7-DHC. By diverting the spread of damage caused by peroxyl radicals from

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (3)
Cholesterol biosynthesis from zymosterol (modified Kandutsch-Russell pathway)Cholesterol biosynthesis via desmosterol (Bloch pathway)Activation of gene expression by SREBF (SREBP)
MECANISMO DE DOENÇA

Lathosterolosis

An autosomal recessive disorder characterized by multiple congenital anomalies affecting axial and appendicular skeleton, liver, central nervous and urogenital systems, and lysosomal storage.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
86.1 TPM
Fígado
72.7 TPM
Vagina
46.5 TPM
Esôfago - Mucosa
45.9 TPM
Próstata
43.2 TPM
OUTRAS DOENÇAS (1)
lathosterolosis
HGNC:10547UniProt:O75845
SCARB2Lysosome membrane protein 2Candidate gene tested inTolerante
FUNÇÃO

Acts as a lysosomal receptor for glucosylceramidase (GBA1) targeting (Microbial infection) Acts as a receptor for enterovirus 71

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 4, with or without renal failure

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM4 is an autosomal recessive form associated with renal failure in some cases. Cognitive function is preserved.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
119.7 TPM
Fibroblastos
117.7 TPM
Pulmão
114.5 TPM
Cervix Endocervix
105.3 TPM
Artéria coronária
99.7 TPM
OUTRAS DOENÇAS (3)
action myoclonus-renal failure syndromeGaucher disease type IUnverricht-Lundborg syndrome
HGNC:1665UniProt:Q14108
GBA1Lysosomal acid glucosylceramidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose (PubMed:15916907, PubMed:24211208, PubMed:32144204, PubMed:39395789, PubMed:9201993). Plays a central role in the degradation of complex lipids and the turnover of cellular membranes (PubMed:27378698). Through the production of ceramides, participates in the PKC-activ

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Gaucher disease

An autosomal recessive lysosomal storage disease due to deficient activity of lysosomal beta-glucocerebrosidase, and characterized by accumulation of glucosylceramide in the reticulo-endothelial system. GD is a multisystem disease historically divided into three main subtypes on the basis of the presence of neurologic involvement, age at onset and progression rate: type 1 is the non-neuropathic form, type 2 is the acute neuropathic form with early onset and rapid neurologic deterioration, type 3 is the chronic neuropathic form with slow progression of neurologic features. GD shows a marked phenotypic diversity ranging from adult asymptomatic forms, at the mild end, to perinatal lethal forms at the severe end of the disease spectrum. Formal diagnosis of Gaucher disease is based on the measurement of glucocerebrosidase levels in circulating leukocytes and molecular genetic analysis.

OUTRAS DOENÇAS (7)
Gaucher disease type IIGaucher disease perinatal lethalGaucher disease-ophthalmoplegia-cardiovascular calcification syndromeGaucher disease type I
HGNC:4177UniProt:P04062
PIGKGPI-anchor transamidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the glycosylphosphatidylinositol-anchor (GPI-anchor) transamidase (GPI-T) complex that catalyzes the formation of the linkage between a proprotein and a GPI-anchor and participates in GPI anchored protein biosynthesis (PubMed:10793132, PubMed:11483512, PubMed:12582175, PubMed:34576938, PubMed:35165458, PubMed:35551457, PubMed:37684232, PubMed:9356492). Recognizes diverse proproteins at a C-terminal signal peptide (CSP) region that lacks consensus sequence and replaces it wit

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Attachment of GPI anchor to uPAR
MECANISMO DE DOENÇA

Neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures

An autosomal recessive neurodevelopmental disorder characterized by global developmental delay, intellectual disability, hypotonia, cerebellar ataxia, cerebellar atrophy, delayed motor skills, poor or absent speech, and epilepsy in most patients. Some patients manifest facial dysmorphism. Disease onset is in infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
31.3 TPM
Artéria coronária
22.7 TPM
Artéria tibial
22.5 TPM
Aorta
22.0 TPM
Nervo tibial
17.6 TPM
OUTRAS DOENÇAS (1)
neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures
HGNC:HGNC:8965UniProt:Q92643
PMPCBMitochondrial-processing peptidase subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the essential mitochondrial processing protease (MPP), which cleaves the mitochondrial sequence off newly imported precursors proteins (Probable) (PubMed:29576218). Preferentially, cleaves after an arginine at position P2 (By similarity). Required for PINK1 turnover by coupling PINK1 mitochondrial import and cleavage, which results in subsequent PINK1 proteolysis (PubMed:22354088)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Mitochondrial protein importProcessing of SMDT1
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 6

An autosomal recessive, neurodegenerative disorder characterized by basal ganglia lesions, cerebellar atrophy, and neurologic regression in the first year of life. Common features include truncal hypotonia, lack of independent ambulation, poor speech, intellectual disability, and motor abnormalities, such as ataxia, dystonia, and spasticity.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
85.0 TPM
Ovário
68.1 TPM
Cervix Endocervix
66.3 TPM
Útero
65.9 TPM
Artéria tibial
64.7 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 6
HGNC:9119UniProt:O75439
PIGTGPI-anchor transamidase component PIGTDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the glycosylphosphatidylinositol-anchor (GPI-anchor) transamidase (GPI-T) complex that catalyzes the formation of the linkage between a proprotein and a GPI-anchor and participates in GPI anchored protein biosynthesis (PubMed:11483512, PubMed:12582175, PubMed:28327575, PubMed:34576938, PubMed:35165458, PubMed:35551457, PubMed:36970549, PubMed:37684232). May play a crucial role in GPI-T complex assembly in the luminal layer (PubMed:35165458, PubMed:35551457). Binds GPI-anchor (PubMed

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Attachment of GPI anchor to uPAR
MECANISMO DE DOENÇA

Multiple congenital anomalies-hypotonia-seizures syndrome 3

An autosomal recessive syndrome characterized by distinct facial features, intellectual disability, hypotonia and seizures, in combination with abnormal skeletal, endocrine, and ophthalmologic findings including impaired vision, as well as abnormal motility of the eyes.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
53.6 TPM
Artéria coronária
42.9 TPM
Artéria tibial
38.8 TPM
Útero
35.9 TPM
Fibroblastos
35.5 TPM
OUTRAS DOENÇAS (2)
multiple congenital anomalies-hypotonia-seizures syndrome 3paroxysmal nocturnal hemoglobinuria 2
HGNC:14938UniProt:Q969N2
LIPALysosomal acid lipase/cholesteryl ester hydrolaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the deacylation of cholesteryl ester core lipids of endocytosed low density lipoproteins to generate free fatty acids and cholesterol (PubMed:15269241, PubMed:1718995, PubMed:7204383, PubMed:8112342, PubMed:9633819). Hydrolyzes triglycerides (1,2,3-triacylglycerol) and diglycerides (such as 1,2-diacylglycerol and 1,3-diacylglycerol) with preference for the acyl moieties at the sn-1 or sn-3 positions (PubMed:7204383, PubMed:8112342)

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
LDL clearance
MECANISMO DE DOENÇA

Cholesteryl ester storage disease

An autosomal recessive, mild form of lysosomal acid lipase deficiency characterized by accumulation of cholesteryl esters and triglycerides primarily in the liver. The clinical presentation is highly variable depending on residual levels of lysosomal acid lipase activity, and ranges from early onset of severe cirrhosis to later onset of more slowly progressive hepatic disease with survival into adulthood. Age at onset varies from childhood to adulthood.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Baço
154.8 TPM
Brain Spinal cord cervical c-1
96.2 TPM
Fibroblastos
73.7 TPM
Tecido adiposo
60.9 TPM
Pulmão
50.6 TPM
OUTRAS DOENÇAS (2)
Wolman diseasecholesteryl ester storage disease
HGNC:6617UniProt:P38571
MSMO1Methylsterol monooxygenase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the three-step monooxygenation required for the demethylation of 4,4-dimethyl and 4alpha-methylsterols, which can be subsequently metabolized to cholesterol (PubMed:21285510, PubMed:23583456, PubMed:26114596, PubMed:28673550, PubMed:36958722). Also involved in drug metabolism, as it can metabolize eldecalcitol (ED-71 or 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)-cholecalciferol), a second-generation vitamin D analog, into 1alpha,2beta,25-trihydroxy vitamin D3; this reaction occurs vi

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Zymostenol biosynthesis via lathosterol (Kandutsch-Russell pathway)Cholesterol biosynthesis via desmosterol (Bloch pathway)
MECANISMO DE DOENÇA

Microcephaly, congenital cataract, and psoriasiform dermatitis

An autosomal recessive inborn error of cholesterol metabolism characterized by accumulation of a large amount of methylsterols, particularly dimethylsterols, in affected individuals. Patients manifest psoriasiform dermatitis, arthralgias, congenital cataracts, microcephaly, and developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
137.5 TPM
Fígado
126.0 TPM
Brain Spinal cord cervical c-1
98.5 TPM
Vagina
83.2 TPM
Skin Not Sun Exposed Suprapubic
79.9 TPM
OUTRAS DOENÇAS (1)
microcephaly-congenital cataract-psoriasiform dermatitis syndrome
HGNC:10545UniProt:Q15800
ISCA2Iron-sulfur cluster assembly 2 homolog, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the maturation of mitochondrial 4Fe-4S proteins functioning late in the iron-sulfur cluster assembly pathway. May be involved in the binding of an intermediate of Fe/S cluster assembly

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Maturation of TCA enzymes and regulation of TCA cycleMitochondrial iron-sulfur cluster biogenesis
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 4

A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
21.5 TPM
Linfócitos
20.0 TPM
Glândula adrenal
18.8 TPM
Fibroblastos
18.2 TPM
Testículo
17.7 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 4
HGNC:19857UniProt:Q86U28
SLC10A1Hepatic sodium/bile acid cotransporterCandidate gene tested inTolerante
FUNÇÃO

As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins (PubMed:14660639, PubMed:24867799, PubMed:34060352, PubMed:8132774). It is strictly dependent on the extracellular presence of sodium (PubMed:14660639, PubMed:24867799, PubMed:34060352, PubMed:8132774). It exhibits broad substrate specificity and transports variou

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Recycling of bile acids and salts
MECANISMO DE DOENÇA

Hypercholanemia, familial, 2

An autosomal recessive inborn error of metabolism characterized by persistently increased plasma levels of conjugated bile salts apparent from infancy, fat malabsorption and impaired absorption of fat-soluble vitamins, including D and K. Most patients are asymptomatic. Some neonates may have transient jaundice or transiently elevated liver enzymes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
94.3 TPM
Testículo
0.5 TPM
Cerebelo
0.4 TPM
Cérebro - Hemisfério cerebelar
0.4 TPM
Pituitária
0.2 TPM
OUTRAS DOENÇAS (2)
hypercholanemia, familial, 2hypercholanemia, familial 1
HGNC:10905UniProt:Q14973
LCATPhosphatidylcholine-sterol acyltransferaseDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs) (PubMed:10329423, PubMed:19065001, PubMed:26195816). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
HDL remodeling
MECANISMO DE DOENÇA

Lecithin-cholesterol acyltransferase deficiency

A disorder of lipoprotein metabolism characterized by inadequate esterification of plasmatic cholesterol. Two clinical forms are recognized: complete LCAT deficiency and fish-eye disease. LCATD is generally referred to the complete form which is associated with absence of both alpha and beta LCAT activities resulting in esterification anomalies involving both HDL (alpha-LCAT activity) and LDL (beta-LCAT activity). It causes a typical triad of diffuse corneal opacities, target cell hemolytic anemia, and proteinuria with renal failure.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
117.3 TPM
Cerebelo
88.0 TPM
Tireoide
74.1 TPM
Nervo tibial
68.3 TPM
Cervix Endocervix
63.3 TPM
OUTRAS DOENÇAS (2)
fish eye diseaseNorum disease
HGNC:6522UniProt:P04180
HADHATrifunctional enzyme subunit alpha, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:1550553, PubMed:29915090, PubMed:30850536, PubMed:8135828, PubMed:31604922). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specific

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (8)
Acyl chain remodeling of CLBeta oxidation of hexanoyl-CoA to butanoyl-CoABeta oxidation of octanoyl-CoA to hexanoyl-CoABeta oxidation of decanoyl-CoA to octanoyl-CoA-CoABeta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
MECANISMO DE DOENÇA

Mitochondrial trifunctional protein deficiency 1

An autosomal recessive metabolic disorder of long-chain fatty acid oxidation, biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. The disease phenotype ranges from a fatal form characterized by early-onset cardiomyopathy, cardiac failure and early death to less severe, late-onset forms with myopathy, recurrent rhabdomyolysis, and sensorimotor axonal neuropathy as key features.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
343.5 TPM
Coração - Ventrículo esquerdo
215.7 TPM
Linfócitos
203.7 TPM
Fibroblastos
194.0 TPM
Esôfago - Muscular
182.5 TPM
OUTRAS DOENÇAS (4)
long chain 3-hydroxyacyl-CoA dehydrogenase deficiencymitochondrial trifunctional protein deficiency 1mitochondrial trifunctional protein deficiencyacute fatty liver of pregnancy
HGNC:4801UniProt:P40939
PIGLN-acetylglucosaminyl-phosphatidylinositol de-N-acetylaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the second step of glycosylphosphatidylinositol (GPI) biosynthesis, which is the de-N-acetylation of N-acetylglucosaminyl-phosphatidylinositol

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Coloboma, congenital heart disease, ichthyosiform dermatosis, impaired intellectual development, and ear anomalies syndrome

An extremely rare autosomal recessive multisystem disorder clinically characterized by colobomas, congenital heart defects, migratory ichthyosiform dermatosis, intellectual disability, and ear anomalies including conductive hearing loss. Other clinical features include distinctive facial features, abnormal growth, genitourinary abnormalities, seizures, and feeding difficulties.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
16.6 TPM
Skin Sun Exposed Lower leg
14.9 TPM
Nervo tibial
14.8 TPM
Tireoide
14.1 TPM
Mama
13.1 TPM
OUTRAS DOENÇAS (2)
CHIME syndromehyperphosphatasia-intellectual disability syndrome
HGNC:8966UniProt:Q9Y2B2
DHCR77-dehydrocholesterol reductaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Oxidoreductase that catalyzes the last step of the cholesterol synthesis pathway, which transforms cholesta-5,7-dien-3beta-ol (7-dehydrocholesterol,7-DHC) into cholesterol by reducing the C7-C8 double bond of its sterol core (PubMed:25637936, PubMed:38297129, PubMed:38297130, PubMed:9465114, PubMed:9634533). Can also metabolize cholesta-5,7,24-trien-3beta-ol (7-dehydrodemosterol, 7-DHD) to desmosterol, which is then metabolized by the Delta(24)-sterol reductase (DHCR24) to cholesterol (By simila

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (3)
Cholesterol biosynthesis from zymosterol (modified Kandutsch-Russell pathway)Cholesterol biosynthesis via desmosterol (Bloch pathway)Activation of gene expression by SREBF (SREBP)
MECANISMO DE DOENÇA

Smith-Lemli-Opitz syndrome

An autosomal recessive frequent inborn disorder of sterol metabolism with characteristic congenital malformations and intellectual disability. Children with SLOS have elevated serum 7-dehydrocholesterol (7-DHC) levels and low serum cholesterol levels. SLOS occurs in relatively high frequency: approximately 1 in 20,000 to 30,000 births in populations of northern and central European background. Historically, a clinical distinction often was made between classic ('type I') SLOS and the more severely affected ('type II') patients. There is, in reality, a clinical and biochemical continuum from mild to severe SLOS.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
73.6 TPM
Skin Not Sun Exposed Suprapubic
64.0 TPM
Ovário
60.3 TPM
Fígado
60.2 TPM
Glândula adrenal
58.2 TPM
OUTRAS DOENÇAS (1)
Smith-Lemli-Opitz syndrome
HGNC:2860UniProt:Q9UBM7
NADK2NAD kinase 2, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Mitochondrial NAD(+) kinase that phosphorylates NAD(+) to yield NADP(+). Can use both ATP or inorganic polyphosphate as the phosphoryl donor. Also has weak NADH kinase activity in vitro; however NADH kinase activity is much weaker than the NAD(+) kinase activity and may not be relevant in vivo

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Nicotinate metabolismMitochondrial protein degradation
MECANISMO DE DOENÇA

2,4-dienoyl-CoA reductase deficiency

A rare, autosomal recessive, inborn error of polyunsaturated fatty acids and lysine metabolism, resulting in mitochondrial dysfunction. Affected individuals have a severe encephalopathy with neurologic and metabolic abnormalities beginning in early infancy. Laboratory studies show increased C10:2 carnitine levels and hyperlysinemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
74.6 TPM
Artéria tibial
32.3 TPM
Cervix Ectocervix
32.2 TPM
Testículo
32.1 TPM
Bladder
30.7 TPM
OUTRAS DOENÇAS (1)
progressive encephalopathy with leukodystrophy due to DECR deficiency
HGNC:26404UniProt:Q4G0N4
FLGFibroblast growth factor receptor 1Candidate gene tested inTolerante
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activati

LOCALIZAÇÃO

Cell membraneNucleusCytoplasm, cytosolCytoplasmic vesicle

VIAS BIOLÓGICAS (1)
Formation of the cornified envelope
MECANISMO DE DOENÇA

Pfeiffer syndrome

A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).

EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Sun Exposed Lower leg
431.7 TPM
Skin Not Sun Exposed Suprapubic
229.7 TPM
Esôfago - Mucosa
3.2 TPM
Vagina
1.1 TPM
Ovário
1.0 TPM
OUTRAS DOENÇAS (3)
autosomal dominant ichthyosis vulgarisrecessive X-linked ichthyosisdermatitis, atopic, 2
HGNC:3748UniProt:P11362
GLRX5Glutaredoxin-related protein 5, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Monothiol glutaredoxin involved in mitochondrial iron-sulfur (Fe/S) cluster transfer (PubMed:20364084, PubMed:23615440). Receives 2Fe/2S clusters from scaffold protein ISCU and mediates their transfer to apoproteins, to the 4Fe/FS cluster biosynthesis machinery, or export from mitochondrion (PubMed:20364084, PubMed:23615440, PubMed:24334290). Required for normal regulation of hemoglobin synthesis by the iron-sulfur protein ACO1 (PubMed:20364084)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial iron-sulfur cluster biogenesis
MECANISMO DE DOENÇA

Anemia, sideroblastic, 3, pyridoxine-refractory

A form of sideroblastic anemia, a bone marrow disorder defined by the presence of pathologic iron deposits in erythroblast mitochondria. Sideroblastic anemia is characterized by anemia of varying severity, hypochromic peripheral erythrocytes, systemic iron overload secondary to chronic ineffective erythropoiesis, and the presence of bone marrow ringed sideroblasts. Sideroblasts are characterized by iron-loaded mitochondria clustered around the nucleus. SIDBA3 is refractory to treatment with vitamin B6, while iron chelation therapy may result in clinical improvement. SIDBA3 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
65.0 TPM
Glândula adrenal
55.8 TPM
Músculo esquelético
48.2 TPM
Ovário
43.3 TPM
Rim - Medula
42.5 TPM
OUTRAS DOENÇAS (2)
spasticity-ataxia-gait anomalies syndromesideroblastic anemia 3
HGNC:20134UniProt:Q86SX6
SPTLC2Serine palmitoyltransferase 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases (PubMed:19416851, PubMed:19648650, PubMed:20504773, PubMed:20920666). The SPT complex is composed of SPTLC1, SPTLC2 or SPTLC3 and SPTSSA or SPTSSB. Within this complex, the heterodimer consisting of SPTLC1 and SPTLC2/SPTLC3 forms the catalytic core

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Sphingolipid de novo biosynthesis
MECANISMO DE DOENÇA

Neuropathy, hereditary sensory and autonomic, 1C

A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by prominent sensory abnormalities with a variable degree of motor and autonomic dysfunction. The neurological phenotype is often complicated by severe infections, osteomyelitis, and amputations. HSAN1C symptoms include loss of touch and vibration in the feet, dysesthesia and severe panmodal sensory loss in the upper and lower limbs, distal lower limb sensory loss with ulceration and osteomyelitis, and distal muscle weakness.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
49.9 TPM
Baço
29.7 TPM
Esôfago - Mucosa
26.9 TPM
Adipose Visceral Omentum
25.0 TPM
Tecido adiposo
24.1 TPM
OUTRAS DOENÇAS (2)
neuropathy, hereditary sensory and autonomic, type 1Chereditary sensory and autonomic neuropathy type 1
HGNC:11278UniProt:O15270
DLDDihydrolipoyl dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipoamide dehydrogenase is a component of the glycine cleavage system as well as an E3 component of three alpha-ketoacid dehydrogenase complexes (pyruvate-, alpha-ketoglutarate-, and branched-chain amino acid-dehydrogenase complex) (PubMed:15712224, PubMed:16442803, PubMed:16770810, PubMed:17404228, PubMed:20160912, PubMed:20385101). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion (PubMed:29211711). A fraction of the 2-oxoglutarate dehydrogenase complex also locali

LOCALIZAÇÃO

Mitochondrion matrixNucleusCell projection, cilium, flagellumCytoplasmic vesicle, secretory vesicle, acrosome

VIAS BIOLÓGICAS (10)
BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIVBranched-chain amino acid catabolismBranched-chain ketoacid dehydrogenase kinase deficiencyH139Hfs13* PPM1K causes a mild variant of MSUDSignaling by Retinoic Acid
MECANISMO DE DOENÇA

Dihydrolipoamide dehydrogenase deficiency

An autosomal recessive metabolic disorder characterized biochemically by a combined deficiency of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC), pyruvate dehydrogenase complex (PDC), and alpha-ketoglutarate dehydrogenase complex (KGDC). Clinically, affected individuals have lactic acidosis and neurologic deterioration due to sensitivity of the central nervous system to defects in oxidative metabolism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.2 TPM
Coração - Ventrículo esquerdo
70.7 TPM
Músculo esquelético
69.5 TPM
Esôfago - Muscular
69.5 TPM
Glândula adrenal
69.1 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E3 deficiency
HGNC:2898UniProt:P09622
HMGCS2Hydroxymethylglutaryl-CoA synthase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the first irreversible step in ketogenesis, condensing acetyl-CoA to acetoacetyl-CoA to form HMG-CoA, which is converted by HMG-CoA reductase (HMGCR) into mevalonate

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (3)
Synthesis of Ketone BodiesPPARA activates gene expressionMitochondrial protein degradation
MECANISMO DE DOENÇA

3-hydroxy-3-methylglutaryl-CoA synthase-2 deficiency

A metabolic disorder characterized by severe hypoketotic hypoglycemia, encephalopathy, and hepatomegaly.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
748.5 TPM
Cólon transverso
218.1 TPM
Testículo
67.2 TPM
Estômago
59.6 TPM
Glândula salivar
47.1 TPM
OUTRAS DOENÇAS (1)
3-hydroxy-3-methylglutaryl-CoA synthase deficiency
HGNC:5008UniProt:P54868
PANK2Pantothenate kinase 2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial isoform that catalyzes the phosphorylation of pantothenate to generate 4'-phosphopantothenate in the first and rate-determining step of coenzyme A (CoA) synthesis (PubMed:15659606, PubMed:16272150, PubMed:17242360, PubMed:17825826). Required for angiogenic activity of umbilical vein of endothelial cells (HUVEC) (PubMed:30221726) Cytoplasmic isoform that catalyzes the phosphorylation of pantothenate to generate 4'-phosphopantothenate in the first and rate-determining step of coenzym

LOCALIZAÇÃO

MitochondrionMitochondrion intermembrane spaceNucleusCytoplasm

VIAS BIOLÓGICAS (1)
Coenzyme A biosynthesis
MECANISMO DE DOENÇA

Neurodegeneration with brain iron accumulation 1

Autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. Clinical manifestations include progressive muscle spasticity, hyperreflexia, muscle rigidity, dystonia, dysarthria, and intellectual deterioration which progresses to severe dementia over several years. It is clinically classified into classic, atypical, and intermediate phenotypes. Classic forms present with onset in first decade, rapid progression, loss of independent ambulation within 15 years. Atypical forms have onset in second decade, slow progression, maintenance of independent ambulation up to 40 years later. Intermediate forms manifest onset in first decade with slow progression or onset in second decade with rapid progression. Patients with early onset tend to also develop pigmentary retinopathy, whereas those with later onset tend to also have speech disorders and psychiatric features. All patients have the 'eye of the tiger' sign on brain MRI.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
18.2 TPM
Linfócitos
17.1 TPM
Cerebelo
15.5 TPM
Fibroblastos
15.4 TPM
Testículo
14.7 TPM
OUTRAS DOENÇAS (3)
pantothenate kinase-associated neurodegenerationatypical pantothenate kinase-associated neurodegenerationclassic pantothenate kinase-associated neurodegeneration
HGNC:15894UniProt:Q9BZ23
HEXBBeta-hexosaminidase subunit betaCandidate gene tested inTolerante
FUNÇÃO

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:8123671, PubMed:8672428, PubMed:9694901). The isozyme B does not hydrolyze each of these substrates, however hydrolyzes efficiently neutral oligosaccharide (PubMed:11707436). Only the isozyme A is responsible for the degradation of GM2 gangliosides in

LOCALIZAÇÃO

LysosomeCytoplasmic vesicle, secretory vesicle, Cortical granule

VIAS BIOLÓGICAS (1)
Defective HEXB causes GM2G2 (Hyaluronan metabolism)
MECANISMO DE DOENÇA

GM2-gangliosidosis 2

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. Clinically indistinguishable from GM2-gangliosidosis type 1, presenting startle reactions, early blindness, progressive motor and mental deterioration, macrocephaly and cherry-red spots on the macula.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
137.7 TPM
Aorta
121.2 TPM
Cervix Endocervix
116.9 TPM
Cervix Ectocervix
109.4 TPM
Glândula salivar
107.6 TPM
OUTRAS DOENÇAS (4)
Sandhoff diseaseSandhoff disease, adult formSandhoff disease, infantile formSandhoff disease, juvenile form
HGNC:4879UniProt:P07686
SMPD1Sphingomyelin phosphodiesteraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts sphingomyelin to ceramide (PubMed:12563314, PubMed:1840600, PubMed:18815062, PubMed:25339683, PubMed:25920558, PubMed:27659707, PubMed:33163980). Exists as two enzymatic forms that arise from alternative trafficking of a single protein precursor, one that is targeted to the endolysosomal compartment, whereas the other is released extracellularly (PubMed:20807762, PubMed:21098024, PubMed:9660788). However, in response to various forms of stress, lysosomal exocytosis may represent a major

LOCALIZAÇÃO

LysosomeLipid dropletSecretedSecreted, extracellular space

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Niemann-Pick disease A

An early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, intellectual disability, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
79.4 TPM
Tireoide
67.2 TPM
Pituitária
65.9 TPM
Aorta
63.0 TPM
Cerebelo
61.4 TPM
OUTRAS DOENÇAS (2)
Niemann-Pick disease type BNiemann-Pick disease type A
HGNC:11120UniProt:P17405
MECREnoyl-[acyl-carrier-protein] reductase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters in mitochondrial fatty acid synthesis (fatty acid synthesis type II). Fatty acid chain elongation in mitochondria uses acyl carrier protein (ACP) as an acyl group carrier, but the enzyme accepts both ACP and CoA thioesters as substrates in vitro. Displays a preference for medium-chain over short- and long-chain substrates (PubMed:12654921, PubMed:18479707, PubMed:27817865). May provide the octanoyl chain used for lipoic acid bio

LOCALIZAÇÃO

MitochondrionCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
MECANISMO DE DOENÇA

Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities

An autosomal recessive neurologic disorder characterized by childhood-onset dystonia, basal ganglia degeneration and optic atrophy with decreased visual acuity. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYTOABG severity is variable, and some patients lose independent ambulation.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
16.3 TPM
Nervo tibial
15.9 TPM
Útero
15.8 TPM
Cervix Endocervix
15.2 TPM
Cervix Ectocervix
14.8 TPM
OUTRAS DOENÇAS (3)
dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalitiesoptic atrophy 16obsolete autosomal recessive optic atrophy
HGNC:19691UniProt:Q9BV79
GM2AGanglioside GM2 activatorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents them in soluble form to beta-hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

GM2-gangliosidosis AB

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the presence of both normal hexosaminidase A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
105.2 TPM
Vagina
90.7 TPM
Skin Not Sun Exposed Suprapubic
85.3 TPM
Skin Sun Exposed Lower leg
78.9 TPM
Esôfago - Mucosa
77.5 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
Tay-Sachs disease AB variant
HGNC:4367UniProt:P17900
PIGYPhosphatidylinositol N-acetylglucosaminyltransferase subunit YDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:16162815). May act by regulating the catalytic subunit PIGA (PubMed:16162815)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 6

An autosomal recessive, multisystem disorder characterized by severe developmental delay, dysmorphism, seizures, cataracts, and early death in some patients.

OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 6hyperphosphatasia-intellectual disability syndrome
HGNC:28213UniProt:Q3MUY2
KCTD7BTB/POZ domain-containing protein KCTD7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the control of excitability of cortical neurons

LOCALIZAÇÃO

Cell membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 3, with or without intracellular inclusions

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM3 is an autosomal recessive, severe, form with early onset. Multifocal myoclonic seizures begin between 16 and 24 months of age after normal initial development. Neurodegeneration and regression occur with seizure onset. Other features include intellectual disability, dysarthria, truncal ataxia, and loss of fine finger movements. EEG shows slow dysrhythmia, multifocal and occasionally generalized epileptiform discharges. In some patients, ultrastructural findings on skin biopsies identify intracellular accumulation of autofluorescent lipopigment storage material, consistent with neuronal ceroid lipofuscinosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
27.6 TPM
Útero
24.4 TPM
Cervix Ectocervix
23.9 TPM
Brain Spinal cord cervical c-1
23.6 TPM
Testículo
22.7 TPM
OUTRAS DOENÇAS (1)
progressive myoclonic epilepsy type 3
HGNC:21957UniProt:Q96MP8
HADHBTrifunctional enzyme subunit beta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:29915090, PubMed:30850536, PubMed:8135828). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specificity for long-chain fatty acids (P

LOCALIZAÇÃO

MitochondrionMitochondrion inner membraneMitochondrion outer membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (8)
Acyl chain remodeling of CLBeta oxidation of hexanoyl-CoA to butanoyl-CoABeta oxidation of octanoyl-CoA to hexanoyl-CoABeta oxidation of decanoyl-CoA to octanoyl-CoA-CoABeta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
MECANISMO DE DOENÇA

Mitochondrial trifunctional protein deficiency 2

An autosomal recessive metabolic disorder of long-chain fatty acid oxidation, biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. The disease phenotype ranges from a fatal form characterized by early-onset cardiomyopathy, cardiac failure and early death to less severe, late-onset forms with myopathy, recurrent rhabdomyolysis, and sensorimotor axonal neuropathy as key features.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
375.3 TPM
Coração - Ventrículo esquerdo
307.5 TPM
Coração - Átrio
223.3 TPM
Glândula adrenal
186.5 TPM
Esôfago - Muscular
129.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial trifunctional protein deficiency 2mitochondrial trifunctional protein deficiency
HGNC:4803UniProt:P55084
ETFAElectron transfer flavoprotein subunit alpha, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Heterodimeric electron transfer flavoprotein that accepts electrons from several mitochondrial dehydrogenases, including acyl-CoA dehydrogenases, glutaryl-CoA and sarcosine dehydrogenase (PubMed:10356313, PubMed:15159392, PubMed:15975918, PubMed:27499296, PubMed:9334218). It transfers the electrons to the main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase) (PubMed:9334218). Required for normal mitochondrial fatty acid oxidation and normal amino acid metabol

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Respiratory electron transport
MECANISMO DE DOENÇA

Glutaric aciduria 2A

An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
144.9 TPM
Músculo esquelético
109.5 TPM
Glândula adrenal
101.8 TPM
Coração - Ventrículo esquerdo
98.5 TPM
Fígado
90.9 TPM
OUTRAS DOENÇAS (3)
multiple acyl-CoA dehydrogenase deficiencymultiple acyl-CoA dehydrogenase deficiency, mild typemultiple acyl-CoA dehydrogenase deficiency, severe neonatal type
HGNC:3481UniProt:P13804
NPC1NPC intracellular cholesterol transporter 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Intracellular cholesterol transporter which acts in concert with NPC2 and plays an important role in the egress of cholesterol from the endosomal/lysosomal compartment (PubMed:10821832, PubMed:12554680, PubMed:18772377, PubMed:27238017, PubMed:9211849, PubMed:9927649). Unesterified cholesterol that has been released from LDLs in the lumen of the late endosomes/lysosomes is transferred by NPC2 to the cholesterol-binding pocket in the N-terminal domain of NPC1 (PubMed:18772377, PubMed:19563754, Pu

LOCALIZAÇÃO

Late endosome membraneLysosome membrane

VIAS BIOLÓGICAS (1)
LDL clearance
MECANISMO DE DOENÇA

Niemann-Pick disease C1

A lysosomal storage disorder that affects the viscera and the central nervous system. It is due to defective intracellular processing and transport of low-density lipoprotein derived cholesterol. It causes accumulation of cholesterol in lysosomes, with delayed induction of cholesterol homeostatic reactions. Niemann-Pick disease type C1 has a highly variable clinical phenotype. Clinical features include variable hepatosplenomegaly and severe progressive neurological dysfunction such as ataxia, dystonia and dementia. The age of onset can vary from infancy to late adulthood. An allelic variant of Niemann-Pick disease type C1 is found in people with Nova Scotia ancestry. Patients with the Nova Scotian clinical variant are less severely affected.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
39.4 TPM
Fibroblastos
32.1 TPM
Glândula adrenal
31.5 TPM
Pulmão
30.3 TPM
Nervo tibial
24.6 TPM
OUTRAS DOENÇAS (6)
Niemann-Pick disease, type C1Niemann-Pick disease type C, late infantile neurologic onsetNiemann-Pick disease type C, juvenile neurologic onsetNiemann-Pick disease type C, severe perinatal form
HGNC:7897UniProt:O15118
PNPLA6Patatin-like phospholipase domain-containing protein 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Phospholipase B that deacylates intracellular phosphatidylcholine (PtdCho), generating glycerophosphocholine (GroPtdCho). This deacylation occurs at both sn-2 and sn-1 positions of PtdCho. Catalyzes the hydrolysis of several naturally occurring membrane-associated lipids (PubMed:11927584). Hydrolyzes lysophospholipids and monoacylglycerols, preferring the 1-acyl to the 2-acyl isomer. Does not catalyze hydrolysis of di- or triacylglycerols or fatty acid amides (PubMed:11927584)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Glycerophospholipid catabolism
MECANISMO DE DOENÇA

Spastic paraplegia 39, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG39 is associated with a motor axonopathy affecting upper and lower limbs and resulting in progressive wasting of distal upper and lower extremity muscles.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
75.4 TPM
Pulmão
74.4 TPM
Baço
65.5 TPM
Pituitária
51.6 TPM
Sangue
49.8 TPM
OUTRAS DOENÇAS (5)
hereditary spastic paraplegia 39trichomegaly-retina pigmentary degeneration-dwarfism syndromeataxia-hypogonadism-choroidal dystrophy syndromeLaurence-Moon syndrome
HGNC:16268UniProt:Q8IY17
SUMF1Formylglycine-generating enzymeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Oxidase that catalyzes the conversion of cysteine to 3-oxoalanine on target proteins, using molecular oxygen and an unidentified reducing agent (PubMed:12757706, PubMed:15657036, PubMed:15907468, PubMed:16368756, PubMed:21224894, PubMed:25931126). 3-oxoalanine modification, which is also named formylglycine (fGly), occurs in the maturation of arylsulfatases and some alkaline phosphatases that use the hydrated form of 3-oxoalanine as a catalytic nucleophile (PubMed:12757706, PubMed:15657036, PubM

LOCALIZAÇÃO

Endoplasmic reticulum lumen

VIAS BIOLÓGICAS (2)
The activation of arylsulfatasesGlycosphingolipid catabolism
MECANISMO DE DOENÇA

Multiple sulfatase deficiency

A clinically and biochemically heterogeneous disorder caused by the simultaneous impairment of all sulfatases, due to defective post-translational modification and activation. It combines features of individual sulfatase deficiencies such as metachromatic leukodystrophy, mucopolysaccharidosis, chondrodysplasia punctata, hydrocephalus, ichthyosis, neurologic deterioration and developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
20.9 TPM
Aorta
17.9 TPM
Tireoide
16.0 TPM
Artéria coronária
14.4 TPM
Esôfago - Mucosa
13.6 TPM
OUTRAS DOENÇAS (1)
mucosulfatidosis
HGNC:20376UniProt:Q8NBK3
STSSteryl-sulfataseCandidate gene tested inAltamente restrito
FUNÇÃO

Catalyzes the conversion of sulfated steroid precursors, such as dehydroepiandrosterone sulfate (DHEA-S) and estrone sulfate to the free steroid

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, microneme membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
The activation of arylsulfatasesGlycosphingolipid catabolism
MECANISMO DE DOENÇA

Ichthyosis, X-linked

A keratinization disorder manifesting with mild erythroderma and generalized exfoliation of the skin within a few weeks after birth. Affected boys later develop large, polygonal, dark brown scales, especially on the neck, extremities, trunk, and buttocks.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
26.2 TPM
Fibroblastos
18.9 TPM
Artéria coronária
17.0 TPM
Tecido adiposo
16.7 TPM
Linfócitos
16.3 TPM
OUTRAS DOENÇAS (2)
recessive X-linked ichthyosissyndromic recessive X-linked ichthyosis
HGNC:11425UniProt:P08842
GRNProgranulinCandidate gene tested inTolerante
FUNÇÃO

Secreted protein that acts as a key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing and cell proliferation (PubMed:12526812, PubMed:18378771, PubMed:28073925, PubMed:28453791, PubMed:28541286). Regulates protein trafficking to lysosomes, and also the activity of lysosomal enzymes (PubMed:28453791, PubMed:28541286). Also facilitates the acidification of lysosomes, causing degradation of mature CTSD by CTSB (PubMed:28073925). In addition, functions as

LOCALIZAÇÃO

SecretedLysosome

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Frontotemporal dementia 2

A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. Gestural apraxia, parkinsonism, visual loss, and visual hallucinations are present in 25 to 40% of patients.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
503.8 TPM
Baço
384.4 TPM
Pulmão
354.8 TPM
Sangue
300.9 TPM
Fibroblastos
292.5 TPM
OUTRAS DOENÇAS (5)
neuronal ceroid lipofuscinosis 11GRN-related frontotemporal lobar degeneration with Tdp43 inclusionssemantic dementiaprogressive non-fluent aphasia
HGNC:4601UniProt:P28799
CHKBCholine/ethanolamine kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Has a key role in phospholipid metabolism, and catalyzes the first step of phosphatidylethanolamine and phosphatidylcholine biosynthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Synthesis of PCSynthesis of PE
MECANISMO DE DOENÇA

Muscular dystrophy, congenital, megaconial type

An autosomal recessive, congenital muscular dystrophy characterized by early-onset muscle wasting, intellectual disability, and dilated cardiomyopathy in half of affected individuals. Some patients may die from cardiomyopathy in the first or second decade of life. Muscle biopsy shows peculiar enlarged mitochondria that are prevalent toward the periphery of the fibers but are sparse in the center.

OUTRAS DOENÇAS (2)
megaconial type congenital muscular dystrophyproximal myopathy with focal depletion of mitochondria
HGNC:1938UniProt:Q9Y259
ARSLArylsulfatase LCandidate gene tested inAltamente restrito
FUNÇÃO

Exhibits arylsulfatase activity towards the artificial substrate 4-methylumbelliferyl sulfate (PubMed:7720070, PubMed:9497243). May be essential for the correct composition of cartilage and bone matrix during development (PubMed:7720070). Has no activity toward steroid sulfates (PubMed:7720070)

LOCALIZAÇÃO

Golgi apparatus, Golgi stack

VIAS BIOLÓGICAS (2)
The activation of arylsulfatasesGlycosphingolipid catabolism
MECANISMO DE DOENÇA

Chondrodysplasia punctata 1, X-linked recessive

A clinically and genetically heterogeneous disorder characterized by punctiform calcification of the bones. CDPX1 is a congenital defect of bone and cartilage development characterized by aberrant bone mineralization, severe underdevelopment of nasal cartilage, and distal phalangeal hypoplasia. This disease can also be induced by inhibition with the drug warfarin.

INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
X-linked chondrodysplasia punctata 1
HGNC:719UniProt:P51690
AMACRAlpha-methylacyl-CoA racemaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the interconversion of (R)- and (S)-stereoisomers of alpha-methyl-branched-chain fatty acyl-CoA esters (PubMed:10655068, PubMed:11060359, PubMed:7649182). Acts only on coenzyme A thioesters, not on free fatty acids, and accepts as substrates a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis), and arylpropionic acids like the anti-inflammatory drug ibuprofen (2-(4-isobutylphenyl)propionic acid) but neither

LOCALIZAÇÃO

PeroxisomeMitochondrion

VIAS BIOLÓGICAS (4)
Beta-oxidation of pristanoyl-CoASynthesis of bile acids and bile salts via 24-hydroxycholesterolSynthesis of bile acids and bile salts via 7alpha-hydroxycholesterolPeroxisomal protein import
MECANISMO DE DOENÇA

Alpha-methylacyl-CoA racemase deficiency

A rare autosomal recessive peroxisomal disorder characterized by elevated plasma concentrations of pristanic acid C27-bile-acid intermediates, and adult onset of variable neurodegenerative symptoms affecting the central and peripheral nervous systems. Features may include seizures, visual failure, sensorimotor neuropathy, spasticity, migraine, and white matter hyperintensities on brain imaging.

OUTRAS DOENÇAS (2)
congenital bile acid synthesis defect 4alpha-methylacyl-CoA racemase deficiency
HGNC:451UniProt:Q9UHK6
ABCA1Phospholipid-transporting ATPase ABCA1Candidate gene tested inRestrito
FUNÇÃO

Catalyzes the translocation of specific phospholipids from the cytoplasmic to the extracellular/lumenal leaflet of membrane coupled to the hydrolysis of ATP (PubMed:24097981, PubMed:35974019). Thereby, participates in phospholipid transfer to apolipoproteins to form nascent high density lipoproteins/HDLs (PubMed:14754908). Transports preferentially phosphatidylcholine over phosphatidylserine (PubMed:24097981). May play a similar role in the efflux of intracellular cholesterol to apolipoproteins

LOCALIZAÇÃO

Cell membraneEndosome

VIAS BIOLÓGICAS (2)
PPARA activates gene expressionNR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
MECANISMO DE DOENÇA

Tangier disease

An autosomal recessive disorder characterized by near absence of plasma high density lipoproteins, low serum HDL cholesterol, and massive tissue deposition of cholesterol esters. Clinical features include large yellow-orange tonsils, hepatomegaly, splenomegaly, enlarged lymph nodes, and often sensory polyneuropathy.

OUTRAS DOENÇAS (2)
hypoalphalipoproteinemia, primary, 1Tangier disease
HGNC:29UniProt:O95477
AKR1D1Aldo-keto reductase family 1 member D1Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the stereospecific NADPH-dependent reduction of the C4-C5 double bond of bile acid intermediates and steroid hormones carrying a delta(4)-3-one structure to yield an A/B cis-ring junction. This cis-configuration is crucial for bile acid biosynthesis and plays important roles in steroid metabolism. Capable of reducing a broad range of delta-(4)-3-ketosteroids from C18 (such as, 17beta-hydroxyestr-4-en-3-one) to C27 (such as, 7alpha-hydroxycholest-4-en-3-one)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (3)
Synthesis of bile acids and bile salts via 24-hydroxycholesterolSynthesis of bile acids and bile salts via 7alpha-hydroxycholesterolSynthesis of bile acids and bile salts via 27-hydroxycholesterol
MECANISMO DE DOENÇA

Congenital bile acid synthesis defect 2

A condition characterized by jaundice, intrahepatic cholestasis and hepatic failure. Patients with this liver disease show absence or low levels of chenodeoxycholic acid and cholic acid in plasma and urine.

OUTRAS DOENÇAS (1)
congenital bile acid synthesis defect 2
HGNC:388UniProt:P51857
ACAT1Sterol O-acyltransferase 1Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol (PubMed:16154994, PubMed:16647063, PubMed:32433613, PubMed:32433614, PubMed:32944968, PubMed:9020103). Plays a role in lipoprotein assembly and dietary cholesterol absorption (PubMed:16154994, PubMed:9020103). Preferentially utilizes oleoyl-CoA ((9Z)-octadecenoyl-CoA) as a substrate: shows a higher activity towards an acyl-CoA substrate with a double bond at the delta-9 position (9Z) th

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Branched-chain amino acid catabolismUtilization of Ketone BodiesSynthesis of Ketone BodiesMaturation of TCA enzymes and regulation of TCA cycleMitochondrial protein degradation
VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
beta-ketothiolase deficiency
HGNC:93UniProt:P35610
APOBApolipoprotein B-100Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor

LOCALIZAÇÃO

CytoplasmSecretedLipid droplet

VIAS BIOLÓGICAS (8)
Platelet sensitization by LDLHeme signalingScavenging by Class B ReceptorsCell surface interactions at the vascular wallLDL remodeling
MECANISMO DE DOENÇA

Hypobetalipoproteinemia, familial, 1

A disorder of lipid metabolism characterized by less than 5th percentile age- and sex-specific levels of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia.

OUTRAS DOENÇAS (3)
hypercholesterolemia, autosomal dominant, type Bfamilial hypobetalipoproteinemia 1homozygous familial hypercholesterolemia
HGNC:603UniProt:P04114
APOA5Apolipoprotein A-VDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from mac

LOCALIZAÇÃO

SecretedEarly endosomeLate endosomeGolgi apparatus, trans-Golgi network

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Hypertriglyceridemia 1

A common inherited disorder in which the concentration of very low density lipoprotein (VLDL) is elevated in the plasma. This leads to increased risk of heart disease, obesity, and pancreatitis. Inheritance is autosomal dominant.

OUTRAS DOENÇAS (2)
hyperlipoproteinemia type Vhypertriglyceridemia 1
HGNC:17288UniProt:Q6Q788
ACADVLVery long-chain acyl-CoA dehydrogenase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Very long-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation (FAO), breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (PubMed:17564966, PubMed:18227065, PubMed:7668252, PubMed:9461620, PubMed:9599005, PubMed:9839948). The first step of FAO consists in the proR-proR stereospecific alpha, beta-dehydrogenation of fatty acyl-CoA thioesters using the electron transf

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Beta oxidation of palmitoyl-CoA to myristoyl-CoAXBP1(S) activates chaperone genes
MECANISMO DE DOENÇA

Acyl-CoA dehydrogenase very long-chain deficiency

An inborn error of mitochondrial fatty acid beta-oxidation which leads to impaired long-chain fatty acid beta-oxidation. It is clinically heterogeneous, with three major phenotypes: a severe childhood form characterized by early onset, high mortality and high incidence of cardiomyopathy; a milder childhood form with later onset, characterized by hypoketotic hypoglycemia, low mortality and rare cardiomyopathy; an adult form, with isolated skeletal muscle involvement, rhabdomyolysis and myoglobinuria, usually triggered by exercise or fasting.

OUTRAS DOENÇAS (1)
very long chain acyl-CoA dehydrogenase deficiency
HGNC:92UniProt:P49748
ABCG8ATP-binding cassette sub-family G member 8Candidate gene tested inTolerante
FUNÇÃO

ABCG5 and ABCG8 form an obligate heterodimer that mediates Mg(2+)- and ATP-dependent sterol transport across the cell membrane. Plays an essential role in the selective transport of the dietary cholesterol in and out of the enterocytes and in the selective sterol excretion by the liver into bile (PubMed:11099417, PubMed:11452359, PubMed:15054092, PubMed:27144356). Required for normal sterol homeostasis (PubMed:11099417, PubMed:11452359, PubMed:15054092). The heterodimer with ABCG5 has ATPase act

LOCALIZAÇÃO

Cell membraneApical cell membrane

VIAS BIOLÓGICAS (3)
ABC transporters in lipid homeostasisDefective ABCG5 causes sitosterolemiaNR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
MECANISMO DE DOENÇA

Gallbladder disease 4

One of the major digestive diseases. Gallstones composed of cholesterol (cholelithiasis) are the common manifestations in western countries. Most people with gallstones, however, remain asymptomatic through their lifetimes.

OUTRAS DOENÇAS (4)
sitosterolemia 1homozygous familial hypercholesterolemiasitosterolemiagallbladder disease 4
HGNC:13887UniProt:Q9H221
CLN8Protein CLN8Candidate gene tested inTolerante
FUNÇÃO

Could play a role in cell proliferation during neuronal differentiation and in protection against cell death

LOCALIZAÇÃO

Endoplasmic reticulum membraneEndoplasmic reticulum-Golgi intermediate compartment membraneEndoplasmic reticulum

MECANISMO DE DOENÇA

Ceroid lipofuscinosis, neuronal, 8

A form of neuronal ceroid lipofuscinosis with onset in childhood. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 8 comprise mixed combinations of granular, curvilinear, and fingerprint profiles.

OUTRAS DOENÇAS (2)
neuronal ceroid lipofuscinosis 8neuronal ceroid lipofuscinosis 8 northern epilepsy variant
HGNC:2079UniProt:Q9UBY8
ALDH3A2Aldehyde dehydrogenase family 3 member A2Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the oxidation of medium and long chain aliphatic aldehydes to fatty acids. Active on a variety of saturated and unsaturated aliphatic aldehydes between 6 and 24 carbons in length (PubMed:18035827, PubMed:18182499, PubMed:22633490, PubMed:25047030, PubMed:9133646, PubMed:9662422). Responsible for conversion of the sphingosine 1-phosphate (S1P) degradation product hexadecenal to hexadecenoic acid (PubMed:22633490)

LOCALIZAÇÃO

Microsome membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
RND1 GTPase cycleRND2 GTPase cycle
MECANISMO DE DOENÇA

Sjoegren-Larsson syndrome

An autosomal recessive neurocutaneous disorder characterized by a combination of severe intellectual disability, spastic di- or tetraplegia and congenital ichthyosis. Ichthyosis is usually evident at birth with varying degrees of erythema and scaling, neurologic symptoms appear in the first or second year of life. Most patients have an IQ of less than 60. Additional clinical features include glistening white spots on the retina, seizures, short stature and speech defects.

OUTRAS DOENÇAS (1)
Sjogren-Larsson syndrome
HGNC:403UniProt:P51648
CYP21A2Steroid 21-hydroxylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

A cytochrome P450 monooxygenase that plays a major role in adrenal steroidogenesis. Catalyzes the hydroxylation at C-21 of progesterone and 17alpha-hydroxyprogesterone to respectively form 11-deoxycorticosterone and 11-deoxycortisol, intermediate metabolites in the biosynthetic pathway of mineralocorticoids and glucocorticoids (PubMed:10602386, PubMed:16984992, PubMed:22014889, PubMed:25855791, PubMed:27721825). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, a

LOCALIZAÇÃO

Endoplasmic reticulum membraneMicrosome membrane

VIAS BIOLÓGICAS (3)
Glucocorticoid biosynthesisEndogenous sterolsMineralocorticoid biosynthesis
MECANISMO DE DOENÇA

Adrenal hyperplasia 3

A form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short adult stature. Four clinical types: 'salt wasting' (SW, the most severe type), 'simple virilizing' (SV, less severely affected patients), with normal aldosterone biosynthesis, 'non-classic form' or late-onset (NC or LOAH) and 'cryptic' (asymptomatic).

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula adrenal
1673.2 TPM
Fígado
17.5 TPM
Ovário
4.6 TPM
Baço
3.3 TPM
Fallopian Tube
3.2 TPM
OUTRAS DOENÇAS (3)
classic congenital adrenal hyperplasia due to 21-hydroxylase deficiencyclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing formclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form
HGNC:2600UniProt:P08686
ABCG5ATP-binding cassette sub-family G member 5Candidate gene tested inTolerante
FUNÇÃO

ABCG5 and ABCG8 form an obligate heterodimer that mediates Mg(2+)- and ATP-dependent sterol transport across the cell membrane (PubMed:27144356). Plays an essential role in the selective transport of dietary plant sterols and cholesterol in and out of the enterocytes and in the selective sterol excretion by the liver into bile (PubMed:11099417, PubMed:11138003, PubMed:15054092, PubMed:27144356). Required for normal sterol homeostasis (PubMed:11099417, PubMed:11138003, PubMed:15054092). The heter

LOCALIZAÇÃO

Cell membraneApical cell membrane

VIAS BIOLÓGICAS (3)
ABC transporters in lipid homeostasisDefective ABCG8 causes GBD4 and sitosterolemiaNR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
MECANISMO DE DOENÇA

Sitosterolemia 2

A form of sitosterolemia, an autosomal recessive metabolic disorder characterized by unregulated intestinal absorption of cholesterol, phytosterols and shellfish sterols, and decreased biliary excretion of dietary sterols into bile. Patients have hypercholesterolemia, very high levels of plant sterols in the plasma, and frequently develop tendon and tuberous xanthomas, accelerated atherosclerosis and premature coronary artery disease.

OUTRAS DOENÇAS (3)
sitosterolemia 2sitosterolemiahomozygous familial hypercholesterolemia
HGNC:13886UniProt:Q9H222
APOC2Apolipoprotein C-IICandidate gene tested inTolerante
FUNÇÃO

Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. Both proapolipoprotein C-II and apolipoprotein C-II can activate lipoprotein lipase. In normolipidemic individuals, it is mainly distributed in the HDL, whereas in hypertriglyceridemic individuals, predominantly found in the VLDL and LDL

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Retinoid metabolism and transport
MECANISMO DE DOENÇA

Hyperlipoproteinemia 1B

Autosomal recessive trait characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis.

OUTRAS DOENÇAS (1)
familial apolipoprotein C-II deficiency
HGNC:609UniProt:P02655
ARSAATPase GET3Candidate gene tested inTolerante
FUNÇÃO

ATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum (PubMed:17382883). Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then targets to the endoplasmic reticulum by membrane-bound receptors GET1/WRB and CAMLG/GET2, where the tail-anchored protein is released for insertion. This process is regulated by ATP binding and hydrolysis. ATP binding drives the homodimer towards the closed dime

LOCALIZAÇÃO

CytoplasmEndoplasmic reticulumNucleus, nucleolus

VIAS BIOLÓGICAS (2)
The activation of arylsulfatasesGlycosphingolipid catabolism
MECANISMO DE DOENÇA

Cardiomyopathy, dilated, 2H

A form of dilated cardiomyopathy, a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. CMD2H is an autosomal recessive form characterized by rapid progression and death in early infancy.

OUTRAS DOENÇAS (3)
metachromatic leukodystrophy, juvenile formmetachromatic leukodystrophy, late infantile formmetachromatic leukodystrophy, adult form
HGNC:713UniProt:O43681

Medicamentos e terapias

SIMVASTATINPhase 4

Mecanismo: HMG-CoA reductase inhibitor

EZETIMIBEPhase 4

Mecanismo: Niemann-Pick C1-like protein 1 inhibitor

AMLODIPINE BESYLATEPhase 4

Mecanismo: Voltage-gated L-type calcium channel blocker

PITAVASTATIN CALCIUMPhase 4

Mecanismo: HMG-CoA reductase inhibitor

ALIROCUMABPhase 4

Mecanismo: Subtilisin/kexin type 9 inhibitor

EVOLOCUMABPhase 4

Mecanismo: Subtilisin/kexin type 9 inhibitor

EVINACUMABPhase 4

Mecanismo: Angiopoietin-related protein 3 inhibitor

BEMPEDOIC ACIDPhase 4

Mecanismo: ATP-citrate synthase inhibitor

ATORVASTATIN CALCIUMPhase 4

Mecanismo: HMG-CoA reductase inhibitor

MIPOMERSEN SODIUMPhase 4

Mecanismo: Apo-B 100 mRNA antisense inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

706 variantes patogênicas registradas no ClinVar.

🧬 APOE: NM_000041.4(APOE):c.493C>T (p.Arg165Trp) ()
🧬 APOE: NM_000041.4(APOE):c.300_303del (p.Thr101fs) ()
🧬 APOE: GRCh38/hg38 19q13.31-13.32(chr19:44626066-46268105)x3 ()
🧬 APOE: NM_000041.4(APOE):c.*25C>T ()
🧬 APOE: NM_000041.4(APOE):c.237-17C>T ()
Ver todas no ClinVar

Vias biológicas (Reactome)

169 vias biológicas associadas aos genes desta condição.

Nuclear signaling by ERBB4 Scavenging by Class A Receptors Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors Post-translational protein phosphorylation Chylomicron assembly Chylomicron remodeling Chylomicron clearance HDL remodeling NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Retinoid metabolism and transport Amyloid fiber formation Mitochondrial iron-sulfur cluster biogenesis Glycosphingolipid catabolism Platelet degranulation Neutrophil degranulation LDL clearance Keratan sulfate degradation CS/DS degradation MPS IV - Morquio syndrome B (Keratin metabolism) Sialic acid metabolism Defective NEU1 causes sialidosis MPS IV - Morquio syndrome B (CS/DS degradation) Activation of gene expression by SREBF (SREBP) Lanosterol biosynthesis Respiratory electron transport Pregnenolone biosynthesis Endogenous sterols Electron transport from NADPH to Ferredoxin Defective CYP11A1 causes AICSR Initiation of Nuclear Envelope (NE) Reformation Cholesterol biosynthesis via desmosterol (Bloch pathway) RHOA GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle RAC3 GTPase cycle Regulation of MECP2 expression and activity PSAP PSAP(?-?) PSAP(17-524) PSAP(17-524) PSAP(60-142) PSAP(311-391) PSAP(311-391) PSAP(60-142) PSAP(326-340) PSAP(195-273) PSAP is cleaved PSAP fragments ASAP complex, PSAP complex PSAP,CHID1 Signaling by Hippo Apoptotic cleavage of cell adhesion proteins RHOB GTPase cycle Transcriptional regulation of white adipocyte differentiation Assembly of active LPL and LIPC lipase complexes MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis VLDL assembly LDL remodeling E3 ubiquitin ligases ubiquitinate target proteins Peroxisomal protein import Pexophagy Vitamin D (calciferol) metabolism Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Transport of RCbl within the body Androgen biosynthesis Synthesis of bile acids and bile salts Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol Synthesis of bile acids and bile salts via 27-hydroxycholesterol Defective CYP7B1 causes SPG5A and CBAS3 Hyaluronan degradation Defective HEXA causes GM2G1 (Hyaluronan metabolism) Protein methylation Protein lipoylation Cholesterol biosynthesis from zymosterol (modified Kandutsch-Russell pathway) Association of TriC/CCT with target proteins during biosynthesis Attachment of GPI anchor to uPAR Mitochondrial protein import Processing of SMDT1 Zymostenol biosynthesis via lathosterol (Kandutsch-Russell pathway) Maturation of TCA enzymes and regulation of TCA cycle Recycling of bile acids and salts Acyl chain remodeling of CL Beta oxidation of myristoyl-CoA to lauroyl-CoA mitochondrial fatty acid beta-oxidation of unsaturated fatty acids Beta oxidation of palmitoyl-CoA to myristoyl-CoA Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA Beta oxidation of octanoyl-CoA to hexanoyl-CoA Beta oxidation of hexanoyl-CoA to butanoyl-CoA Synthesis of glycosylphosphatidylinositol (GPI) Nicotinate metabolism Mitochondrial protein degradation PI3K Cascade PIP3 activates AKT signaling Signaling by FGFR1 amplification mutants Signaling by activated point mutants of FGFR1 FGFR1b ligand binding and activation FGFR1c ligand binding and activation FGFR1c and Klotho ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer NCAM signaling for neurite out-growth Signal transduction by L1 Phospholipase C-mediated cascade: FGFR1 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling Negative regulation of FGFR1 signaling Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm Sphingolipid de novo biosynthesis Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid Glycine degradation Branched-chain amino acid catabolism OGDH complex synthesizes succinyl-CoA from 2-OG OADH complex synthesizes glutaryl-CoA from 2-OA BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV PDH complex synthesizes acetyl-CoA from PYR Loss-of-function mutations in DBT cause MSUD2 Loss-of-function mutations in DLD cause MSUD3/DLDD Branched-chain ketoacid dehydrogenase kinase deficiency H139Hfs13* PPM1K causes a mild variant of MSUD PPARA activates gene expression Synthesis of Ketone Bodies Coenzyme A biosynthesis Defective HEXB causes GM2G2 (Hyaluronan metabolism) Neddylation Antigen processing: Ubiquitination & Proteasome degradation Glycerophospholipid catabolism The activation of arylsulfatases Metabolism of steroid hormones Synthesis of PC Synthesis of PE Synthesis of bile acids and bile salts via 24-hydroxycholesterol Beta-oxidation of pristanoyl-CoA Defective ABCA1 causes TGD HDL assembly Cell surface interactions at the vascular wall Scavenging by Class B Receptors Scavenging by Class F Receptors Scavenging by Class H Receptors Platelet sensitization by LDL Regulation of TLR by endogenous ligand VLDL clearance Heme signaling XBP1(S) activates chaperone genes ABC transporters in lipid homeostasis Defective ABCG8 causes GBD4 and sitosterolemia Defective ABCG5 causes sitosterolemia Alpha-oxidation of phytanate Class I peroxisomal membrane protein import Insertion of tail-anchored proteins into the endoplasmic reticulum membrane RND2 GTPase cycle RND1 GTPase cycle Sphingolipid catabolism Mineralocorticoid biosynthesis Glucocorticoid biosynthesis Defective CYP21A2 causes AH3

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado10
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 10 medicamentos · 1 ensaio
✓ Aprovados — podem ser usados hoje
SIMVASTATINEZETIMIBEAMLODIPINE BESYLATEPITAVASTATIN CALCIUMALIROCUMABEVOLOCUMABEVINACUMABBEMPEDOIC ACIDATORVASTATIN CALCIUMMIPOMERSEN SODIUM
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Alteração do metabolismo lipídico

Centros de Referência SUS

21 centros habilitados pelo SUS para Alteração do metabolismo lipídico

Centros para Alteração do metabolismo lipídico

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
183 papers (10 anos)
#1

Sitosterolemia Presenting as Lipid Keratopathy and Xanthomas.

Pediatrics2026 Feb 01

Sitosterolemia is a rare autosomal recessive disorder of lipid metabolism, with varied incidence rates of 1/200 000 to 1/1 000 000. The condition often presents prepubertally, but is commonly misdiagnosed as familial hypercholesterolemia. We want to raise clinical suspicion across pediatric generalists and subspecialties with our case report of a 7-year-old girl who presented via ophthalmology following the surgical removal of a lipid keratopathy of her cornea. Four years before her presentation at ophthalmology, she also underwent surgical excision of a large xanthoma from her left buttock. There was no further diagnostic workup at that point. On examination, she had multiple tuberous xanthomas on her knuckles and knees in addition to the corneal deposits. Baseline lipid investigation revealed a markedly elevated total cholesterol of 11.9 mmol/L and an LDL cholesterol of 10.2 mmol/L. She was given a presumptive diagnosis of familial hypercholesterolemia and started on statin therapy, to which she had a partial response. Molecular genetic analysis for familial hypercholesterolemia was negative, but because of the high index of suspicion, an expanded genetics panel was requested that demonstrated compound heterozygous variants in the ABCG5 gene, pathogenic for sitosterolemia. Sterol analysis demonstrated markedly elevated phytosterol levels consistent with the genetic findings. The patient was treated with dietary restriction of plant sterols and Ezetimibe. Computed tomography coronary angiogram showed no coronary artery calcification. An awareness of sitosterolemia amongst pediatricians is vitally important as this condition may present to numerous specialties, as evidenced in this case. Recommended lifestyle and pharmacotherapy interventions differ between sitosterolemia and familial hypercholesterolemia.

#2

Lipid Keratopathy in Sitosterolemia: A Case Report and Review of The Ophthalmic Manifestations.

Cornea2026 Jan 20

The aim of this study was to describe the case of a 9-year-old girl with inferior arcus in her right cornea and discrete inferior lipid deposition in her left cornea. Serum cholesterol and lipid levels were measured under general anesthesia for treatment with fine-needle cautery and subconjunctival bevacizumab. Serum cholesterol and low-density lipoprotein were elevated at 12 mmol/L (normal range 3-5 mmol/L) and 10.8 mmol/L (normal range <3 mmol/L), respectively. Genetic testing identified a pathogenic variant in the ATP-binding cassette subfamily G member 5 (ABCG5) gene consistent with sitosterolemia, a rare, autosomal recessive disorder of lipid metabolism. Mutations in the ABC genes result in ineffective transport of plant sterols into the intestinal lumen and their subsequent accumulation in the blood. The girl's cholesterol and lipid profile returned to normal following dietary restriction of plant sterol intake and treatment with ezetimibe 10 mg daily and atorvastatin 10 mg daily. This is the first reported case of a discrete lipid deposit at the cornea in a patient with sitosterolemia. Untreated, patients with sitosterolemia can develop coronary artery disease early in life. Ophthalmologists should be aware of the potential for underlying disorders of lipid metabolism in young patients with corneal arcus and/or lipid keratopathy.

#3

Panaxatriol Improves the Disorder of Lipid Metabolism and Intestinal Flora in Rats Fed With a High-Fat Diet.

Chemistry &amp; biodiversity2026 Feb

The ability of ginsenosides to regulate lipid metabolism in vivo and in vitro has been widely studied; however, the effect of panaxatriol (PT) on reducing blood lipids and its impact on intestinal microflora have not been investigated. The results of this study show that PT can not only significantly reduce the level of ALT but also effectively alleviate fatty degeneration and lipid droplet deposition in hepatocytes, thereby improving the pathological damage to the liver. It can also significantly reduce serum TC, TG, and LDL-C levels and increase HDL-C. At the same time, PT can significantly increase SOD activity, decrease MDA content, and inhibit the increase of coagulation factors such as TXB2, thus alleviating vascular endothelial injury. In addition, PT decreased the abundance of intestinal flora, increased the ratio of Firmicutes to Bacteroidetes, increased the abundance of Akkermansia, and decreased the abundance of Prevotella. Our research shows that PT can effectively alleviate the lipid metabolism disorder induced by the high-fat and high-sugar diet by improving liver lipid deposition, enhancing antioxidant capacity, regulating blood coagulation function, and reshaping intestinal flora structure, suggesting that PT has potential application value in the treatment of metabolic syndrome.

#4

Lecithin-Cholesterol Acyltransferase Deficiency as a Rare Cause of Bilateral Corneal Opacities: A Case Report of a Novel Frameshift Mutation.

Case reports in ophthalmology2026

Lecithin-cholesterol acyltransferase (LCAT) deficiency is a rare autosomal recessive disorder of lipid metabolism characterized by corneal opacification, hemolytic anemia, and chronic kidney disease. We describe the ophthalmic, systemic, and genetic findings of a patient with LCAT deficiency and report a novel frameshift mutation in the LCAT gene. Ophthalmic findings may represent the first clinical sign and guide the diagnosis. A 50-year-old white male with end-stage renal disease on hemodialysis and a history of recurrent hemolytic anemia was referred for bilateral corneal opacities. Despite diffuse opacification involving all corneal layers, his best corrected visual acuity remained 20/20 in both eyes with normal color vision, although contrast sensitivity was reduced. Laboratory testing revealed normocytic, normochromic anemia, low HDL cholesterol, and reduced apolipoprotein A levels. Genetic analysis identified compound heterozygosity in the LCAT gene: a novel frameshift variant c.580_598del p.(Ala194Serfs*64), classified as likely pathogenic, and the previously described missense variant c.619G>A p.(Gly207Ser), also classified as likely pathogenic. This case highlights the importance of considering metabolic disorders in the differential diagnosis of bilateral corneal opacities and expands the genetic spectrum of LCAT deficiency by reporting a novel frameshift mutation.

#5

The novel_miR-123 targets SeFas4 to inhibit lipogenesis of Spodoptera exigua post Bacillus thuringiensis GS57 infection.

Pesticide biochemistry and physiology2026 Jan

The infection of Bacillus thuringiensis (Bt) could inhibit the growth and development of the pest by impairing its lipid metabolism. Although miRNAs have been proven to be involved in insect development, reproduction, and immune response, the role of miRNAs in regulating the disorder of lipid metabolism caused by Bt infection remains unclear at the post-transcriptional level. In this study, we found that novel_miR-123 responding to Bt infection was accounted for downregulating the expression of SeFas4 to inhibit the lipogenesis, which lead to delayed development, shortened lifespan, and reduced reproduction of Spodoptera exigua. The regulation relationship between novel_miR-123 and its target gene SeFas4 was subsequently identified using mimics and inhibitor injection, Dual-luciferase reporter assay, and rescue assay. Moreover, the overexpression of novel_miR-123 resulted in reduced lipid accumulation and delayed development, whereas the knockdown of novel_miR-123 resulted in weight gain and excessive lipid accumulation of S. exigua. The rescue assay showed that novel_miR-123 inhibitor could alleviate delayed weight development induced by dsSeFas4, as well as restore the reduced lipid accumulation of S. exigua. In addition, the monitoring of gene expression showed that the novel_miR-123 and SeFas4 mainly responded to Bt GS57 infection in the larval duration stage, implying the important role in larval lipid accumulation. Our findings provide a new insight into the regulation pathway of pest development impaired by Bt infection, consequently identifying a promising target for the development of pest control strategies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC26 artigos no totalmostrando 178

2026

Lipid Keratopathy in Sitosterolemia: A Case Report and Review of The Ophthalmic Manifestations.

Cornea
2026

Panaxatriol Improves the Disorder of Lipid Metabolism and Intestinal Flora in Rats Fed With a High-Fat Diet.

Chemistry &amp; biodiversity
2026

Lecithin-Cholesterol Acyltransferase Deficiency as a Rare Cause of Bilateral Corneal Opacities: A Case Report of a Novel Frameshift Mutation.

Case reports in ophthalmology
2026

Sitosterolemia Presenting as Lipid Keratopathy and Xanthomas.

Pediatrics
2026

The novel_miR-123 targets SeFas4 to inhibit lipogenesis of Spodoptera exigua post Bacillus thuringiensis GS57 infection.

Pesticide biochemistry and physiology
2025

Psychological Framing of Illness: Early Family Trauma and Diagnostic Delay in Adult-Onset Metachromatic Leukodystrophy.

Case reports in psychiatry
2026

Imperatorin ameliorates metabolic dysfunction-associated fatty liver disease through modulating Suv39h1/Fabps/Cept1 signalling pathway.

British journal of pharmacology
2026

Unfriendly dialogue of gut microbiota and lipid metabolism in Alzheimer's disease.

Journal of Alzheimer's disease : JAD
2025

Identification of Riboflavin Metabolism Pathway in HepG2 Cells Expressing Genotype IV Swine Hepatitis E Virus ORF3 Protein.

Veterinary sciences
2025

State-of-the-art review: The value of leveraging evidence and data (LEAD) in pediatric screening for familial hypercholesterolemia.

American journal of preventive cardiology
2025

Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights.

Journal of clinical lipidology
2025

Research advances in current drugs targeting hyperlipidemia (Review).

Molecular medicine reports
2025

Role of Next-Generation Sequencing in Diagnosis of Familial Hypercholesterolemia in Serbia.

Diagnostics (Basel, Switzerland)
2025

Roles of ABCA1 in Chronic Obstructive Pulmonary Disease.

COPD
2025

A Novel Screening Approach for Familial Hypercholesterolemia: A Genetic Study on Patients Detected Using Preexisting Centralized Analytics.

Journal of clinical medicine
2025

Unveiling the roles of HIPK2 in atherosclerosis: Insights into the β-catenin/STAT1 signaling cascade and the involvement of SENP1.

Biochemical pharmacology
2025

How fish intestinal cells responded to dietary methylmercury exposure? A single-cell transcriptomic analysis.

Environmental pollution (Barking, Essex : 1987)
2025

Proteomic analysis reveals the alleviation of follicular development defects in offspring mice under DEHP exposure by melatonin.

BMC biology
2025

Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial.

Atherosclerosis
2025

High burden of disease in patients with homozygous familial hypercholesterolemia despite recent advances in therapies and updated guidelines: A real-world study.

Journal of clinical lipidology
2025

Research Progress on Obesity-Associated Kidney Diseases.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
2024

Therapeutic Persistence in the Management of Familial Hypercholesterolemia: A Case of Acquired PCSK9 Inhibitor Nonresponse.

JACC. Case reports
2024

[Thyroid Hormone Resistance Syndrome Complicated With Papillary Thyroid Carcinoma and Madelung's Disease:Report of One Case].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
2024

Unveiling the comorbidity burden of male breast cancer.

Scientific reports
2024

Bisphenol A induces lipid metabolism disorder and impairs hepatopancreas of Sesarmops sinensis.

Marine pollution bulletin
2024

Dilated cardiomyopathy revealing Refsum disease: a case report.

Journal of medical case reports
2024

Effect of electroacupuncture on the intestinal flora-short chain fatty acid metabolism axis in simple obesity rats.

Zhen ci yan jiu = Acupuncture research
2024

Insulin-like growth factor-binding protein 7 exacerbates inflammatory response and lipid metabolism imbalance in alcohol-associated liver disease.

Free radical biology &amp; medicine
2024

Astragaloside IV attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2024

The Correlation between Depression during Pregnancy and Metabolic Syndrome.

Actas espanolas de psiquiatria
2024

Beneficial effects of Dendrobium officinale National Herbal Drink on metabolic immune crosstalk via regulate SCFAs-Th17/Treg.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2024

Fagopyrum Dibotrys Rhizoma regulates pulmonary lipid metabolic homeostasis and the ERK-cPLA2 pathway to alleviate asthma in mice.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2024

Implementation of a primary-tertiary shared care model to improve the detection of familial hypercholesterolaemia (FH): a mixed methods pre-post implementation study protocol.

BMJ open
2024

Effect of circadian rhythm change on gut microbiota and the development of nonalcoholic fatty liver disease in mice.

Sleep medicine
2024

Dietary pterostilbene exerts potential protective effects by regulating lipid metabolism and enhancing antioxidant capacity on liver in broilers.

Journal of animal physiology and animal nutrition
2024

ACOX1 deficiency-induced lipid metabolic disorder facilitates chronic interstitial fibrosis development in renal allografts.

Pharmacological research
2024

Familial ApoB-specific familial hypobetalipoproteinemia in a patient with non-classical congenital adrenal hyperplasia.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
2024

Analysis of fecal microbiome and metabolome changes in goats with pregnant toxemia.

BMC veterinary research
2024

Promote lipolysis in white adipocytes by magnetic hyperthermia therapy with Fe3O4microsphere-doped hydrogel.

Nanotechnology
2024

Polymethoxyflavones in citrus extract has a beneficial effect on hypercholesterolemia rats by promoting liver cholesterol metabolism.

Journal of ethnopharmacology
2024

Unraveling the genetic background of individuals with a clinical familial hypercholesterolemia phenotype.

Journal of lipid research
2024

Whole grain germinated brown rice intake modulates the gut microbiota and alleviates hypertriglyceridemia and hypercholesterolemia in high fat diet-fed mice.

Food &amp; function
2023

Metabolomics analysis delineates the therapeutic effects of Yinlan Tiaozhi capsule on triton WR-1339 -induced hyperlipidemia in mice.

Frontiers in pharmacology
2023

Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners.

Kardiologia polska
2024

Isophorone-based AIEgens fluorescent probe with red emission for targeting lipid droplets and identifying non-alcoholic fatty liver disease.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
2023

Lipidomic analysis identified potential predictive biomarkers of statin response in subjects with Familial hypercholesterolemia.

Chemistry and physics of lipids
2023

High-Throughput Microscopy Characterization of Rare LDLR Variants.

JACC. Basic to translational science
2023

Lipid metabolism disorder promotes the development of intervertebral disc degeneration.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2023

Integration of transcriptomics and metabolomics analysis for unveiling the toxicological profile in the liver of mice exposed to uranium in drinking water.

Environmental pollution (Barking, Essex : 1987)
2023

An increase in calculated small dense low-density lipoprotein cholesterol predicts new onset of hypertension in a Japanese cohort.

Hypertension research : official journal of the Japanese Society of Hypertension
2023

Integrated Analysis of Transcriptome and Metabolome Provides Insight into Camellia oleifera Oil Alleviating Fat Accumulation in High-Fat Caenorhabditis elegans.

International journal of molecular sciences
2023

The anti-hyperlipidemic effect and underlying mechanisms of barley (Hordeum vulgare L.) grass polysaccharides in mice induced by a high-fat diet.

Food &amp; function
2023

Ginsenosides Rg1 regulate lipid metabolism and temperature adaptation in Caenorhabditis elegans.

Journal of ginseng research
2023

Study on the therapeutic effect and mechanism of Tangningtongluo Tablet on diabetic mice.

Journal of diabetes and its complications
2023

Regulation of endothelial ferroptosis by SESN1 in atherosclerosis and its related mechanism.

Aging
2023

Niclosamide exposure disrupts antioxidant defense, histology, and the liver and gut transcriptome of Chinese soft-shelled turtle (Pelodiscus sinensis).

Ecotoxicology and environmental safety
2023

[Blueberry attenuates liver injury in metabolic dysfunction-associated liver disease by promoting the expression of mitofilin/Mic60 in human hepatocytes and inhibiting the production of superoxide].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
2023

Glutaminase 1 isoform up-regulation associated with lipid metabolism disorder induced by methyl tertiary-butyl ether in male rats.

Ecotoxicology and environmental safety
2023

Membrane Protein Amuc_1100 Derived from Akkermansia muciniphila Facilitates Lipolysis and Browning via Activating the AC3/PKA/HSL Pathway.

Microbiology spectrum
2023

Lysophosphatidylcholine inhibits lung cancer cell proliferation by regulating fatty acid metabolism enzyme long-chain acyl-coenzyme A synthase 5.

Clinical and translational medicine
2022

Fenofibrate suppresses corneal neovascularization by regulating lipid metabolism through PPARα signaling pathway.

Frontiers in pharmacology
2022

Effect of Lactobacillus rhamnosus hsryfm 1301 Fermented Milk on Lipid Metabolism Disorders in High-Fat-Diet Rats.

Nutrients
2022

Progressive ataxia of cerebrotendinous xanthomatosis with a rare c.255+1G>T splice site mutation: A case report.

World journal of clinical cases
2023

Comparison of developmental toxicity induced by PFOA, HFPO-DA, and HFPO-TA in zebrafish embryos.

Chemosphere
2022

Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis.

Biomedicines
2022

Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism.

Frontiers in pharmacology
2022

Compound green tea (CGT) regulates lipid metabolism in high-fat diet induced mice.

RSC advances
2022

Modulation of the gut microbiota and lipidomic profiles by black chokeberry (Aronia melanocarpa L.) polyphenols via the glycerophospholipid metabolism signaling pathway.

Frontiers in nutrition
2022

Roles of organelle-specific autophagy in hepatocytes in the development and treatment of non-alcoholic fatty liver disease.

Chinese medical journal
2022

Landscape of lipidomic metabolites in gut-liver axis of Sprague-Dawley rats after oral exposure to titanium dioxide nanoparticles.

Particle and fibre toxicology
2022

Toxicity of triphenyl phosphate toward the marine rotifer Brachionus plicatilis: Changes in key life-history traits, rotifer-algae population dynamics and the metabolomic response.

Ecotoxicology and environmental safety
2022

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy.

Pharmacology research &amp; perspectives
2022

Magnesium isoglycyrrhizinate attenuates acute alcohol-induced hepatic steatosis in a zebrafish model by regulating lipid metabolism and ER stress.

Nutrition &amp; metabolism
2022

Adipose Dysfunction in Adulthood Insulin Resistance of Low-Birth Weight Mice: A Proteomics Study.

Diabetes, metabolic syndrome and obesity : targets and therapy
2022

Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice.

Bioengineered
2022

Integrated application of multi-omics approach and biochemical assays provides insights into physiological responses to saline-alkaline stress in the gills of crucian carp (Carassius auratus).

The Science of the total environment
2022

Incidental diagnosis of LPL deficiency in an infant presenting with an acute respiratory infection.

Clinica chimica acta; international journal of clinical chemistry
2022

Hematological Inflammatory Markers in Patients with Clinically Confirmed Familial Hypercholesterolemia.

BioMed research international
2022

Performance comparison of different classification algorithms applied to the diagnosis of familial hypercholesterolemia in paediatric subjects.

Scientific reports
2021

Curcumin ameliorates lipid metabolic disorder and cognitive dysfunction via the ABCA1 transmembrane transport system in APP/PS1 double transgenic mice.

Journal of integrative neuroscience
2021

Tilapia Head Protein Hydrolysate Attenuates Scopolamine-Induced Cognitive Impairment through the Gut-Brain Axis in Mice.

Foods (Basel, Switzerland)
2022

Lipopolysaccharide and tyloxapol accelerate the development of atherosclerosis in mice.

Lipids
2021

Madelung's disease with alcoholic liver disease and acute kidney injury: A case report.

World journal of clinical cases
2021

Characterization of Two Variants at Met 1 of the Human LDLR Gene Encoding the Same Amino Acid but Causing Different Functional Phenotypes.

Biomedicines
2021

The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review.

Diabetes, metabolic syndrome and obesity : targets and therapy
2021

Premature Acute Myocardial Infarction in a Young Patient With Sitosterolemia.

CJC open
2021

Integrated metabolome and transcriptome analyses revealing the effects of thermal stress on lipid metabolism in juvenile turbot Scophthalmus maximus.

Journal of thermal biology
2021

Dietary Sterols and Sterol Oxidation Products on Atherosclerosis: An Insight Provided by Liver Proteomic and Lipidomic.

Molecular nutrition &amp; food research
2021

LDLR variants functional characterization: Contribution to variant classification.

Atherosclerosis
2021

Spatially Resolved Metabolomics Based on Air-Flow-Assisted Desorption Electrospray Ionization-Mass Spectrometry Imaging Reveals Region-Specific Metabolic Alterations in Diabetic Encephalopathy.

Journal of proteome research
2021

Effects of high-fat diet on the formation of depressive-like behavior in mice.

Food &amp; function
2021

High Fat Activates O-GlcNAcylation and Affects AMPK/ACC Pathway to Regulate Lipid Metabolism.

Nutrients
2021

Ginsenoside CK inhibits obese insulin resistance by activating PPARγ to interfere with macrophage activation.

Microbial pathogenesis
2021

Adipose tissue of female Wistar rats respond to Ilex paraguariensis treatment after ovariectomy surgery.

Journal of traditional and complementary medicine
2021

[Effect of the reactive oxygen species-induced by bisphenol A on liver lipid metabolism disorder].

Wei sheng yan jiu = Journal of hygiene research
2021

Metabolic profiling of fatty acids in Tripterygium wilfordii multiglucoside- and triptolide-induced liver-injured rats.

Open life sciences
2020

How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia.

Atherosclerosis. Supplements
2021

Apigenin Ameliorates Insulin Resistance and Lipid Accumulation by Endoplasmic Reticulum Stress and SREBP-1c/SREBP-2 Pathway in Palmitate-Induced HepG2 Cells and High-Fat Diet-Fed Mice.

The Journal of pharmacology and experimental therapeutics
2021

Potential mechanisms underlying the ameliorative effect of Lactobacillus paracasei FZU103 on the lipid metabolism in hyperlipidemic mice fed a high-fat diet.

Food research international (Ottawa, Ont.)
2020

Lipid metabolism-related proteins of relevant evolutionary and lymphoid interest (PRELI) domain containing family proteins in cancer.

American journal of translational research
2020

Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease.

Toxicology
2021

Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata.

Annals of clinical biochemistry
2020

Effects of epoxy stearic acid on lipid metabolism in HepG2 cells.

Journal of food science
2020

Cascade screening and treatment of children with familial hypercholesterolemia in Turkey.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2021

Regulatory roles of circRNAs in adipogenesis and lipid metabolism: emerging insights into lipid-related diseases.

The FEBS journal
2021

Association of body mass index changes from childhood to adulthood with dyslipidemia in adults: Hanzhong adolescent cohort study.

Journal of public health (Oxford, England)
2020

Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.

Drug design, development and therapy
2020

The crosstalk: exosomes and lipid metabolism.

Cell communication and signaling : CCS
2020

Multiomics Profiling Reveals Protective Function of Schisandra Lignans against Acetaminophen-Induced Hepatotoxicity.

Drug metabolism and disposition: the biological fate of chemicals
2020

Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.

Expert opinion on pharmacotherapy
2020

The "discovery" of lipid droplets: A brief history of organelles hidden in plain sight.

Biochimica et biophysica acta. Molecular and cell biology of lipids
2020

Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020.

Current opinion in lipidology
2020

5α,6α-Epoxyphytosterols and 5α,6α-Epoxycholesterol Increase Nitrosative Stress and Inflammatory Cytokine Production in Rats on Low-Cholesterol Diet.

Oxidative medicine and cellular longevity
2022

Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
2020

Fever, Fasting, and Rhabdomyolysis in an Adult Male.

Neurology India
2020

Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning.

European journal of preventive cardiology
2019

The Lipo- Phenotypic Screening Tool for Familial Hypercholesterolaemia.

JPMA. The Journal of the Pakistan Medical Association
2019

Transcriptome analysis reveals mechanism underlying the differential intestinal functionality of laying hens in the late phase and peak phase of production.

BMC genomics
2020

Similar hepatotoxicity response induced by Rhizoma Paridis in zebrafish larvae, cell and rat.

Journal of ethnopharmacology
2020

Effects of di (2-ethylhexyl) phthalate and high-fat diet on lipid metabolism in rats by JAK2/STAT5.

Environmental science and pollution research international
2019

Determination of the Pathological Features of NPC1 Variants in a Cellular Complementation Test.

International journal of molecular sciences
2019

Protective Effects and Mechanisms of Vaccarin on Vascular Endothelial Dysfunction in Diabetic Angiopathy.

International journal of molecular sciences
2019

Effects of fluoride on the histology, lipid metabolism, and bile acid secretion in liver of Bufo gargarizans larvae.

Environmental pollution (Barking, Essex : 1987)
2019

Identifying obesity-related multimorbidity combinations in the United States.

Clinical obesity
2019

Anthraquinones in the aqueous extract of Cassiae semen cause liver injury in rats through lipid metabolism disorder.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2019

Di (2-ethylhexyl) phthalate Disorders Lipid Metabolism via TYK2/STAT1 and Autophagy in Rats.

Biomedical and environmental sciences : BES
2019

Hematopoietic stem cell transplant does not prevent neurological deterioration in infants with Farber disease: Case report and literature review.

JIMD reports
2019

Why systematic literature reviews in Fabry disease should include all published evidence.

European journal of medical genetics
2019

Knockdown expression of MECR, a novel gene of mitochondrial FAS II inhibits growth and colony-formation, promotes apoptosis of hepatocelluar carcinoma cells.

Bioscience trends
2019

Correlation between Obesity and Lipid Profile in Type 2 Diabetes Mellitus Patients at the Endocrine and Metabolic Polyclinic in General Hospital Pirngadi Medan.

Open access Macedonian journal of medical sciences
2019

[Eletroacupuncture improves lipid metabolic disorder by regulating hepatic AMPK/p38 MAPK/RRARγ signaling in rats with high-fat diet-induced insulin resistance].

Zhen ci yan jiu = Acupuncture research
2019

Influence of total polar compounds on lipid metabolism, oxidative stress and cytotoxicity in HepG2 cells.

Lipids in health and disease
2019

Screening of common genetic variants in the APOB gene related to familial hypercholesterolemia in a Saudi population: A case-control study.

Medicine
2018

Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries.

Atherosclerosis
2018

Erchen Decoction Ameliorates Lipid Metabolism by the Regulation of the Protein CAV-1 and the Receptors VLDLR, LDLR, ABCA1, and SRB1 in a High-Fat Diet Rat Model.

Evidence-based complementary and alternative medicine : eCAM
2019

SREBP-1 and LXRα pathways mediated Cu-induced hepatic lipid metabolism in zebrafish Danio rerio.

Chemosphere
2018

Alterations of the Gut Microbiome Associated With the Treatment of Hyperuricaemia in Male Rats.

Frontiers in microbiology
2019

Therapeutic plasma exchange in secondary prevention of acute pancreatitis in pregnant patient with familial hyperchylomicronemia.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
2018

Lipid metabolism and carcinogenesis, cancer development.

American journal of cancer research
2018

Suppression of NF-κB activation by PDLIM2 restrains hepatic lipogenesis and inflammation in high fat diet induced mice.

Biochemical and biophysical research communications
2018

Neutral lipid storage disease with myopathy: Further phenotypic characterization of a rare PNPLA2 variant.

Neuromuscular disorders : NMD
2018

Skin Changes Revealing a Disorder of Lipid Metabolism.

Deutsches Arzteblatt international
2018

Oxidative stress and mitochondrial dysfunction mediated Cd-induced hepatic lipid accumulation in zebrafish Danio rerio.

Aquatic toxicology (Amsterdam, Netherlands)
2018

The brain lipidome in neurodegenerative lysosomal storage disorders.

Biochemical and biophysical research communications
2018

Familial Hypercholesterolemia: Cascade Screening in Children and Relatives of the Affected.

Indian journal of pediatrics
2018

[Effect of Eletroacupuncture Intervention on Insulin Resistance, Lipid Metabolic Disorder and Expression of Hepatic SREBP-1 c and Fatty Acid Synthase Proteins in Rats with Hyperlipidemia].

Zhen ci yan jiu = Acupuncture research
2018

Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis.

Genetics in medicine : official journal of the American College of Medical Genetics
2017

Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics.

International journal of molecular sciences
2017

Detection and management of familial hypercholesterolaemia in primary care in Australia: protocol for a pragmatic cluster intervention study with pre-post intervention comparisons.

BMJ open
2017

PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer.

Oncotarget
2017

Familial Hypercholesterolemia: A Systematic Review of Guidelines on Genetic Testing and Patient Management.

Frontiers in public health
2018

Association of General and Abdominal Obesity With Hypertension, Dyslipidemia and Prediabetes in the PREDAPS Study.

Revista espanola de cardiologia (English ed.)
2017

Preventive effect of L-carnitine on the disorder of lipid metabolism and circadian clock of mice subjected to chronic jet-lag.

Physiological research
2017

Light Chain Myeloma induced Severe Hypertriglyceridemia.

Journal of clinical and diagnostic research : JCDR
2017

Muscle MRI in neutral lipid storage disease (NLSD).

Journal of neurology
2017

Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia.

Journal of clinical lipidology
2017

RNA sequence analysis of rat acute experimental pancreatitis with and without fatty liver: a gene expression profiling comparative study.

Scientific reports
2017

A case of sitosterolemia due to compound heterozygous mutations in ABCG5: clinical features and treatment outcomes obtained with colestimide and ezetimibe.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2016

[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].

Vnitrni lekarstvi
2017

Myocardial layer-specific analysis in patients with heterozygous familial hypercholesterolemia using speckle tracking echocardiography.

Echocardiography (Mount Kisco, N.Y.)
2016

Familial defective apolipoprotein B-100: A review.

Journal of clinical lipidology
2016

Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.

Atherosclerosis
2016

Baicalein protects against oxLDL-caused oxidative stress and inflammation by modulation of AMPK-alpha.

Oncotarget
2016

Coexistence of VHL Disease and CPT2 Deficiency: A Case Report.

Cancer research and treatment
2016

Diagnosis and treatment of familial hypercholesterolemia: The impact of recent guidelines.

The Nurse practitioner
2016

[Study on the prevalence of lipid metabolism disorders and quantitative analysis of apolipoproteins in T2DM patients].

Wei sheng yan jiu = Journal of hygiene research
2016

[An Analysis on the Association between Lipid Metabolism and Low Birth Body Mass and Relative Factors among Rural and Urban Adolescents].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
2015

Longitudinal assessment of reflexive and volitional saccades in Niemann-Pick Type C disease during treatment with miglustat.

Orphanet journal of rare diseases
2015

[Experimental study on intervention effect of Grifola frondosa on nonalcoholic steatohepatitis].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
2015

Homozygous Familial Hypercholesterolemia Associated with Symmetric Subcutaneous Lipomatosis.

Indian journal of dermatology
2015

Molecular-genetic aspects of familial hypercholesterolemia.

Endocrine regulations
2015

Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease.

Diagnostic pathology
2015

Sodium tanshinone IIA sulfonate ameliorates ischemia-induced myocardial inflammation and lipid accumulation in Beagle dogs through NLRP3 inflammasome.

International journal of cardiology
2016

Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement.

Genetics in medicine : official journal of the American College of Medical Genetics
2015

Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis.

International journal of clinical and experimental medicine
2015

Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management.

Cardiology and therapy
2015

Modulation of colon cancer by nutmeg.

Journal of proteome research
2015

Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice.

Biochemical and biophysical research communications

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Alteração do metabolismo lipídico.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Alteração do metabolismo lipídico

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Sitosterolemia Presenting as Lipid Keratopathy and Xanthomas.
    Pediatrics· 2026· PMID 41539482mais citado
  2. Lipid Keratopathy in Sitosterolemia: A Case Report and Review of The Ophthalmic Manifestations.
    Cornea· 2026· PMID 41649375mais citado
  3. Panaxatriol Improves the Disorder of Lipid Metabolism and Intestinal Flora in Rats Fed With a High-Fat Diet.
    Chemistry &amp; biodiversity· 2026· PMID 41643151mais citado
  4. Lecithin-Cholesterol Acyltransferase Deficiency as a Rare Cause of Bilateral Corneal Opacities: A Case Report of a Novel Frameshift Mutation.
    Case reports in ophthalmology· 2026· PMID 41551200mais citado
  5. The novel_miR-123 targets SeFas4 to inhibit lipogenesis of Spodoptera exigua post Bacillus thuringiensis GS57 infection.
    Pesticide biochemistry and physiology· 2026· PMID 41326123mais citado
  6. Case Report: Compound heterozygous familial hypercholesterolemia in a pediatric patient with multiple cutaneous xanthomas.
    Front Pediatr· 2026· PMID 41988157recente
  7. Carnitine Palmitoyltransferase II Deficiency.
    · 1993· PMID 20301431recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:309005(Orphanet)
  2. MONDO:0002525(MONDO)
  3. GARD:21314(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1476525(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Alteração do metabolismo lipídico
Compêndio · Raras BR

Alteração do metabolismo lipídico

ORPHA:309005 · MONDO:0002525
CID-10
E78.9 · Distúrbio não especificado do metabolismo de lipoproteínas
Ensaios
1 ativos
Medicamentos
18 registrados
MedGen
UMLS
C0023772
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Medicamentos (literatura)
fonte: Orphanet